

Alkoxy Pyrazoles as Soluble Guanylate Cyclase Activators

FIELD OF THE INVENTION

This invention relates to heterocyclic compounds which are useful as activators of soluble guanylate cyclase and are thus useful for treating a variety of diseases that are mediated or sustained by decreased or diminished soluble guanylate cyclase activity, including cardiovascular diseases, renal disease, diabetes, fibrotic disorders, urologic disorders, neurological disorders and inflammatory disorders. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

BACKGROUND

Soluble guanylate cyclase (sGC) is a receptor for nitric oxide (NO) which is found in the cytoplasm of many cell types. In humans, functional sGC is a heterodimer composed of either an alpha 1 or alpha 2 subunit combined with the beta 1 subunit which has a heme prosthetic group. Under non-pathophysiological conditions, NO binding to the heme of sGC activates the enzyme to catalyze the conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). cGMP is a second messenger which exerts effects by modulating cGMP dependent protein kinase (PKG) isoforms, phosphodiesterases, and cGMP gated ion channels. In doing so, sGC has been demonstrated to modulate numerous pathways associated with diseases including arterial hypertension, pulmonary hypertension, atherosclerosis, heart failure, liver cirrhosis, renal fibrosis, and erectile dysfunction (O. Evgenov et al., Nature Reviews, 2006, 5, 755-768 and Y. Wang-Rosenke et al., Curr. Med. Chem., 2008, 15, 1396-1406).

Under normal conditions, the iron in sGC exists in the ferrous state which is capable of binding to NO and carbon monoxide (CO). However, under conditions of oxidative stress which can occur in various diseases, published reports indicate that the heme iron becomes oxidized to the ferric state which is incapable of being activated by NO or CO. The inability of NO to signal

through sGC with an oxidized heme iron has been hypothesized to contribute to disease processes. Recently, two novel classes of compounds have been described which potentiate sGC activity in a heme dependent (sGC stimulators) and heme independent (sGC activators) manner. The activity of sGC stimulators synergizes with NO to increase cGMP production while sGC activators are only additive with NO to augment cGMP levels (O. Evgenov et al., *Nature Reviews*, 2006, 5, 755-768). Both stimulators and activators of sGC have demonstrated benefit in animal models of disease. Activators of sGC provide the advantage of being able to preferentially target the diseased, non-functional form of the enzyme. sGC activators include BAY 58-2667 (cinaciguat) (J-P Stasch et al., *Brit J. Pharmacol.*, 2002, 136, 773-783) and HMR-1766 (ataciguat) (U. Schindler et al., 2006, *Mol. Pharmacol.*, 69, 1260-1268).

NO has an important role in maintaining normal cellular and tissue function. However, adequate signaling in the NO pathway can be disrupted at a number of steps. NO signaling can be impaired by reduced levels of nitric oxide synthase (NOS) enzymes, NOS activity, NO bioavailability, sGC levels, and sGC activity. sGC activators have the potential to bypass the functional impediment produced by all of these impairments. Since sGC activation occurs downstream of NO synthesis or NO availability, these deficiencies will not impact the activity of sGC activators. As described above, the activity of sGC in which function is disrupted by heme iron oxidation will be corrected by sGC activators. Thus, sGC activators have the potential to provide benefit in many diseases caused by defective signaling in the NO pathway.

Activation of sGC has the potential to provide therapeutic benefit for atherosclerosis and arteriosclerosis. Cinaciguat treatment has been demonstrated to prevent neointimal hyperplasia after endothelial denudation by wire injury of the carotid artery in rats (K. Hirschberg et al., *Cardiovasc. Res.*, 2010, 87, Suppl. 1, S100, Abstract 343). Ataciguat inhibited atherosclerotic plaque formation in ApoE^{-/-} mice feed a high fat diet (M. van Eickels, *BMC Pharmacology*, 2007, 7, Suppl. 1, S4). Decreased NO production in endothelial nitric oxide synthase (eNOS) deficient mice increased vascular inflammation and insulin resistance in response to nutrient excess. In the same study, the phosphodiesterase 5 (PDE5) inhibitor sildenafil reduced vascular inflammation and insulin resistance in mice fed a high-fat diet (N. Rizzo et al., *Arterioscler. Thromb. Vasc. Biol.*, 2010, 30, 758-765). Lastly, after balloon-injury of rat carotid arteries in

vivo, a sGC stimulator (YC-1) inhibited neointima formation (C. Wu, J. Pharmacol. Sci., 2004, 94, 252-260).

The complications of diabetes may be reduced by sGC activation. Glucose induced suppression of glucagon release is lost in pancreatic islets that lack PKG, thus suggesting a role of sGC mediated cGMP production in glucose regulation (V. Leiss et al., BMC Pharmacology, 2009, 9, Suppl. 1, P40).

It is well established clinically that elevation of cGMP by treatment with PDE5 inhibitors is efficacious for the treatment of erectile dysfunction (ED). However, 30% of ED patients are resistant to PDE5 inhibitor treatment (S. Gur et al., Curr. Pharm. Des., 2010, 16, 1619-1633). The sGC stimulator BAY-41-2272 is able to relax corpus cavernosum muscle in a sGC dependent manner, thus suggesting that increased sGC activity could provide benefit in ED patients (C. Teixeira et al., J. Pharmacol. & Exp. Ther., 2007, 322, 1093-1102). Furthermore, sGC stimulators and sGC activators used individually or either in combination with PDE5 inhibitor was able to treat ED in animal models (WO 10/081647).

There is evidence that sGC activation may be useful in preventing tissue fibrosis, including that of the lung, liver, and kidney. The processes of epithelial to mesenchymal transition (EMT) and fibroblast to myofibroblast conversion are believed to contribute to tissue fibrosis. When either cincaciguat or BAY 41-2272 was combined with sildenafil, lung fibroblast to myofibroblast conversion was inhibited (T. Dunkern et al., Eur. J. Pharm., 2007, 572, 12-22). NO is capable of inhibiting EMT of alveolar epithelial cells (S. Vyas-Read et al., Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 293, 1212-1221), suggesting that sGC activation is involved in this process. NO has also been shown to inhibit glomerular TGF beta signaling (E. Dreieicher et al., J. Am. Soc. Nephrol., 2009, 20, 1963-1974) which indicates that sGC activation may be able to inhibit glomerular sclerosis. In a pig serum model and carbon tetrachloride model of liver fibrosis, an sGC activator (BAY 60-2260) was effective at inhibiting fibrosis (A. Knorr et al., Arzneimittel-Forschung, 2008, 58, 71-80).

Clinical studies have demonstrated efficacy using the sGC activator cinaciguat for the treatment of acute decompensated heart failure (H. Lapp et al., *Circulation*, 2009, 119, 2781-2788). This is consistent with results from a canine tachypacing-induced heart failure model in which acute intravenous infusion of cinaciguat was able to produce cardiac unloading (G. Boerrigter et al., *Hypertension*, 2007, 49, 1128-1133). In a rat myocardial infarction induced chronic heart failure model, HMR 1766 improved cardiac function and reduced cardiac fibrosis which was further potentiated by ramipril (F. Daniela, *Circulation*, 2009, 120, Suppl. 2, S852-S853).

Activators of sGC can be used to treat hypertension. This has been clearly demonstrated in clinical studies in which the dose of cinaciguat is titrated based on the magnitude of blood pressure reduction achieved (H. Lapp et al., *Circulation*, 2009, 119, 2781-2788). Preclinical studies using cinaciguat had previously shown the ability of sGC activation to reduce blood pressure (J.-P. Stasch et al., 2006, *J. Clin. Invest.*, 116, 2552-2561). Similar findings have been reported using the sGC activator HMR 1766 as well (U. Schindler et al., 2006, *Mol. Pharmacol.*, 69, 1260-1268).

The activation of sGC has the potential to reduce inflammation by effects on the endothelium. BAY 41-2272 and a NO donor inhibited leukocyte rolling and adhesion in eNOS deficient mice. This was demonstrated to be mediated by down-regulation of expression of the adhesion molecule P-selectin (A. Ahluwalia et al., *Proc. Natl. Acad. Sci. USA*, 2004, 101, 1386-1391). Inhibitors of NOS and sGC were shown to increase endotoxin (LPS) induced ICAM expression on mesenteric microcirculation vessels. This was reduced by an NO donor in a cGMP dependent manner. Treatment of mice with NOS or sGC inhibitors increased neutrophil migration, rolling, and adhesion induced by LPS or carrageenin (D. Dal Secco, *Nitric Oxide*, 2006, 15, 77-86). Activation of sGC has been shown to produce protection from ischemia-reperfusion injury using BAY 58-2667 in both in vivo and in an isolated heart model (T. Krieg et al., *Eur. Heart J.*, 2009, 30, 1607-6013). Similar results were obtained using the same compound in a canine model of cardioplegic arrest and extracorporeal circulation (T. Radovits et al., *Eur J. Cardiothorac. Surg.*, 2010).

Some studies have indicated the potential of sGC activation to have antinociceptive effects. In streptozotocin-induced diabetes models of nociception in mice (writhing assay) and rats (paw hyperalgesia), elevation of cGMP levels by administration of sildenafil blocked the pain response, which in turn was abrogated by a NOS or sGC inhibitor (C. Patil et al., *Pharm.*, 2004, 72, 190-195). The sGC inhibitor 1*H*-1,2,4-oxadiazolo[4,2-*a*]quinoxalin-1-one (ODQ) has been demonstrated to block the antinociceptive effects of various agents including meloxicam and diphenyl diselenide in a formalin induced pain model (P. Aguirre-Banuelos et al., *Eur. J. Pharmacol.*, 2000, 395, 9-13 and L. Savegnago et al., *J. Pharmacy Pharmacol.*, 2008, 60, 1679-1686) and xylazine in a paw pressure model (T. Romero et al., *Eur. J. Pharmacol.*, 2009, 613, 64-67). Furthermore, ataciguat was antinociceptive in the carrageenan model of inflammatory triggered thermal hyperalgesia and the spared nerve injury model of neuropathic pain in mice (WO 09/043495).

Inhibitor of PDE9, a phosphodiesterase specific for cGMP expressed in the brain, has been shown to improve long-term potentiation (F. van der Staay et al., *Neuropharmacol.* 2008, 55, 908-918). In the central nervous system, sGC is the primary enzyme which catalyzes the formation of cGMP (K. Domek-Lopacinska et al., *Mol. Neurobiol.*, 2010, 41, 129-137). Thus, sGC activation may be beneficial in treating Alzheimer's and Parkinson's disease.

In a phase II clinical study, the sGC stimulator riociguat, was efficacious in treating chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension (H. Ghofrani et al., *Eur. Respir. J.*, 2010, 36, 792-799). These findings extend the preclinical studies in which BAY 41-2272 and cinaciguat reduced pulmonary hypertension in mouse (R. Dumitrascu et al., *Circulation*, 2006, 113, 286-295) and lamb (O. Evgenov et al., 2007, *Am. J. Respir. Crit. Care Med.*, 176, 1138-1145) models. Similar results were obtained using HMR 1766 in a mouse model of pulmonary hypertension (N. Weissmann et al., 2009, *Am. J. Physiol. Lung Cell. Mol. Physiol.*, 297, L658-665).

Activation of sGC has the potential to treat chronic kidney disease. Both BAY 58-2667 and HMR 1766 improved renal function and structure in a rat subtotal nephrectomy model of kidney disease (P. Kalk et al., 2006, *Brit. J. Pharmacol.*, 148, 853-859 and K. Benz et al., 2007, *Kidney Blood Press. Res.*, 30, 224-233). Improved kidney function and survival was provided by BAY

58-2667 treatment in hypertensive renin transgenic rats (TG(mRen2)27 rats) treated with a NOS inhibitor (J.-P. Stasch et al., 2006, *J. Clin. Invest.*, 116, 2552-2561). BAY 41-2272 treatment preserved kidney function and structure in a chronic model of kidney disease in rats induced by uninephrectomy and anti-thy1 antibody treatment (Y. Wang et al., 2005, *Kidney Intl.*, 68, 47-61). Diseases caused by excessive blood clotting may be treated with sGC activators. Activation of sGC using BAY 58-2667 was capable of inhibiting platelet aggregation induced by various stimuli *ex vivo*. Additionally, this compound inhibited thrombus formation *in vivo* in mice and prolonged bleeding time (J.-P. Stasch et al., 2002, *Brit. J. Pharmacol.*, 136, 773-783). In another study using HMR 1766, *in vivo* platelet activation was inhibited in streptozotocin treated rats (A. Schafer et al., 2006, *Arterioscler. Thromb. Vasc. Biol.*, 2006, 26, 2813-2818).

sGC activation may also be beneficial in the treatment of urologic disorders (WO/08138483). This is supported by clinical studies using the PDE5 inhibitor vardenafil (C. Stief et al., 2008, *Eur. Urol.*, 53, 1236-1244). The soluble guanylate cyclase stimulator BAY 41-8543 was able to inhibit prostatic, urethra, and bladder smooth muscle cell proliferation using patient samples (B. Fibbi et al., 2010, *J. Sex. Med.*, 7, 59-69), thus providing further evidence supporting the utility of treating urologic disorders with sGC activators.

The above studies provide evidence for the use of sGC activators to treat cardiovascular diseases including hypertension, atherosclerosis, peripheral artery disease, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, thromboembolic pulmonary hypertension, pulmonary arterial hypertension, stable and unstable angina, thromboembolic disorders. Additionally, sGC activators have the potential to treat renal disease, diabetes, fibrotic disorders including those of the liver, kidney and lungs, urologic disorders including overactive bladder, benign prostatic hyperplasia, and erectile dysfunction, and neurological disorders including Alzheimer's disease, Parkinson's disease, as well as neuropathic pain. Treatment with sGC activators may also provide benefits in inflammatory disorders such as psoriasis, multiple sclerosis, arthritis, asthma, and chronic obstructive pulmonary disease.


BRIEF SUMMARY

The present disclosure provides novel compounds which activate or potentiate sGC and are thus useful for treating a variety of diseases and disorders that can be alleviated by sGC activation or potentiation including cardiovascular, inflammatory and renal diseases. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present disclosure provides activators of soluble guanylate cyclase having solubility properties consistent with acceptable pharmacokinetic properties. As is known in the art, poorly soluble compounds may suffer from poor human exposure. The compounds of the present disclosure would be expected to have exposure properties consistent with being a suitable drug.

The present disclosure provides compounds with metabolic stability properties consistent with acceptable pharmacokinetic properties. As is known in the art, compounds having poor metabolic stability may not readily achieve desirable therapeutic levels. The compounds of the present disclosure would be expected to have metabolic stability properties consistent with being a suitable drug.

In one aspect, the present disclosure provides a compound of the formula I



wherein:

A is a 5-7 membered saturated heterocyclyl group containing one nitrogen and optionally one oxygen, wherein one carbon of said heterocyclyl group is optionally substituted with one or two groups selected from C₁₋₃alkyl and oxo ;

R¹ is C₁₋₄ alkyl optionally substituted with a methoxy group;

R² is selected from H, F, Cl, C₁₋₃alkyl, -CN, -OMe and -CF₃;

R³ is selected from H and -CH₃;

R⁴ is selected from H, F, -CH₃ and -OMe;

R⁵ is selected from H, Cl, -CH₃, -CH₂CH₃, -CF₃, F, and -OMe;

R⁶ is bonded to the nitrogen on A and is selected from H, C₁₋₆alkyl, -(CH₂)_nC₃₋₆cycloalkyl, -C(O)C₁₋₆alkyl, -(CH₂)_n heterocyclyl, -(CH₂)_n aryl -(CH₂)_n heteroaryl, -SO₂aryl, SO₂C₁₋₆alkyl wherein said C₁₋₆alkyl, -(CH₂)_n heterocyclyl, -(CH₂)_n cycloalkyl, -(CH₂)_n aryl and -(CH₂)_n heteroaryl are optionally substituted with one to four groups independently selected from C₁₋₃alkyl, halogen, C₁₋₃alkoxy, -CF₃, -OH, oxo, -(CH₂)₁₋₃O(CH₂)₂₋₃OH, and -SO₂CH₃;

R⁷ is selected from H, -CH₃, -CH₂CH₃, -CF₃, F, and -CN;

n is 0, 1 or 2

or a salt thereof.


In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound as defined herein and a pharmaceutically acceptable excipient or carrier.

In another aspect, the present disclosure provides a compound as defined herein for use in treating a disease or disorder that can be alleviated by sGC activation or potentiation.

In another aspect, the present disclosure provides use of a compound as defined herein in the manufacture of a medicament for the treatment of a disease or disorder selected from the group consisting of a cardiovascular disease, inflammatory disease, hepatic fibrotic disorder, renal fibrotic disorder, pulmonary fibrotic disorder and cardiac fibrotic disorder.

DETAILED DESCRIPTION OF THE INVENTION

In an embodiment, there are provided compounds of the formula I



wherein:

A is a 5-7 membered saturated heterocyclyl group containing one nitrogen and optionally one oxygen, wherein one carbon of said heterocyclyl group is optionally substituted with one or two groups selected from C_{1-3} alkyl and oxo ;

R^1 is C_{1-4} alkyl optionally substituted with a methoxy group;

R^2 is selected from H, F, Cl, C_{1-3} alkyl, -CN, -OMe and -CF₃;

R^3 is selected from H and -CH₃;

R^4 is selected from H, F, -CH₃ and -OMe;

R^5 is selected from H, Cl, -CH₃, -CH₂CH₃, -CF₃, F, and -OMe;

R^6 is bonded to the nitrogen on A and is selected from H, C_{1-6} alkyl, $-(CH_2)_n C_{3-6}$ cycloalkyl, -C(O) C_{1-6} alkyl, $-(CH_2)_n$ heterocyclyl, $-(CH_2)_n$ aryl $-(CH_2)_n$ heteroaryl, -SO₂aryl, SO₂ C_{1-6} alkyl wherein said C_{1-6} alkyl, $-(CH_2)_n$ heterocyclyl, $-(CH_2)_n$ cycloalkyl, $-(CH_2)_n$ aryl and $-(CH_2)_n$

heteroaryl are optionally substituted with one to four groups independently selected from C₁₋₃alkyl, halogen, C₁₋₃alkoxy, -CF₃, -OH, oxo, -(CH₂)₁₋₃O(CH₂)₂₋₃OH, and -SO₂CH₃;

R⁷ is selected from H, -CH₃, -CH₂CH₃, -CF₃, F, and -CN;

n is 0, 1 or 2

or a salt thereof.

In another embodiment, there are provided compounds as described in the embodiment above, wherein:

A is a 5-7 membered saturated heterocyclyl group containing one nitrogen, wherein one carbon of said heterocyclyl group is optionally substituted with one or two C₁₋₃alkyl groups;

R¹ is C₁₋₃alkyl;

R² is selected from H, F, Cl, C₁₋₃alkyl, -CN, -OMe and -CF₃;

R³ is selected from H and -CH₃;

R⁴ is selected from H and F;

R⁵ is selected from H, Cl and -CH₃;

R⁶ is bonded to the nitrogen on A and is selected from H, C₁₋₆alkyl, -(CH₂)_nC₃₋₆cycloalkyl, -C(O)C₁₋₆alkyl, -(CH₂)_n heterocyclyl, -(CH₂)_n aryl and -(CH₂)_n heteroaryl, wherein said C₁₋₆alkyl, -(CH₂)_n heterocyclyl, -(CH₂)_n cycloalkyl, -(CH₂)_n aryl and -(CH₂)_n heteroaryl are optionally substituted with one to four groups independently selected from C₁₋₃alkyl, halogen, C₁₋₃alkoxy, -CF₃, -OH and -SO₂CH₃;

R^7 is H;

and


n is 0, 1 or 2;

or a salt thereof.





In another embodiment, there are provided compounds as described in any of the embodiments above, wherein:

R^1 is methyl, ethyl or isopropyl; and

the group



is selected from:



and

;

or a salt thereof.

In another embodiment there are provided compounds as described in any of the embodiments above, wherein:

R^2 is selected from $-\text{CH}_3$, F, Cl, and $-\text{CF}_3$; and

R^6 is selected from H, C_{1-6} alkyl, $-(\text{CH}_2)_n\text{C}_{3-6}$ cycloalkyl, $-\text{C}(\text{O})\text{C}_{1-6}$ alkyl and $-(\text{CH}_2)_n$ heterocyclyl, wherein said C_{1-6} alkyl, $-(\text{CH}_2)_n$ cycloalkyl and $-(\text{CH}_2)_n$ heterocyclyl are optionally substituted with one to four groups independently selected from C_{1-3} alkyl, halogen, C_{1-3} alkoxy, $-\text{CF}_3$, $-\text{OH}$ and $-\text{SO}_2\text{CH}_3$;

or a salt thereof.

In another embodiment there are provided compounds as described in any of the embodiments above, wherein said heterocyclyl referred to in R^6 is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 2-oxabicyclo[3.2.0]heptanyl, [1,4]dioxanyl, 8-oxabicyclo[3.2.1]octanyl, 1-oxaspiro[4.5]decanyl and pyrrolidin-2-one;

said heteroaryl referred to in R^6 is selected from imidazolyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl and 4,5,6,7-tetrahydrobenzothiazolyl;

and said aryl referred to in R^6 is phenyl;

or a salt thereof.

In another embodiment there are provided compounds as described in any of the embodiments above, wherein:

R^6 is $-(\text{CH}_2)_n$ heterocyclyl, wherein said heterocyclyl is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 2-oxabicyclo[3.2.0]heptanyl, [1,4]dioxanyl, 8-oxabicyclo[3.2.1]octanyl and 1-oxaspiro[4.5]decanyl;

or a salt thereof.

In another embodiment there are provided compounds as described in any of the embodiments above, wherein:

R^2 is $-\text{CH}_3$;

R^3 is H;

R^4 is H or $-\text{CH}_3$;


R^5 is H, or $-\text{CH}_3$;

R^7 is in the position para to R^5 and is H, $-\text{CH}_3$ or $-\text{CH}_2\text{CH}_3$;

or a salt thereof.

In another embodiment there are provided compounds as described in any of the embodiments above, wherein:

the group



or a salt thereof.

In another embodiment there are provided compounds as described in any of the embodiments above, wherein:



R³ is H; and









R⁴ is H;









or a salt thereof.









Table 1 shows representative compounds of the invention which can be made by the general synthetic schemes, the examples, and known methods in the art.









Table 1









Cpd No.	Structure	Cpd No.	Structure
1		2	









3		4	
5		6	
7		8	
9		10	

11		12	
13		14	
15		16	
17		18	









19		20	
21		22	
23		24	
25		26	









27		28	
29		30	
31		32	
33		34	









35		36	
37		38	
39		40	
41		42	









43		44	
45		46	
47		48	
49		50	









51		52	
53		54	
55		56	
57		58	









59		60	
61		62	
63		64	
65		66	









67		68	
69		70	
71		72	
73		74	









75		76	
77		78	
79		80	
81		82	









83		84	
85		86	
87		88	
89		90	









91		92	
93		94	
95		96	
97		98	









99		100	
101		102	
103		104	
105		106	









115		116	
117		118	
119		120	
121		122	









123		124	
125		126	
127		128	
129		130	









131		132	
133		134	
135		136	
137		138	









139		140	
141		142	
143		144	
145		146	









147		148	
149		150	
151		152	
153		154	









163		164	
165		166	
167		168	
169		170	









171		172	
173		174	
175		176	
177		178	









179		180	
181		182	
183		184	
185		186	









187		188	
189		190	
191		192	
193		194	









195		196	
197		198	
199		200	
201		202	









203		204	
205		206	
207		208	
209		210	









211		212	
213		214	
215		216	
217		218	

219		220	
221		222	
223		224	
225		226	

227		228	
229		230	
231		232	
233		234	

235		236	
237		238	
239		240	
241		242	

243		244	
245		246	
247		248	
249		250	

251		252	
253		254	
255		256	
257		258	

In one embodiment, the invention relates to any of the compounds depicted in Table 1 above and the pharmaceutically acceptable salts thereof.

In another embodiment the invention relates to the group of compounds depicted in Table 1 consisting of compound number 1, 2, 3, 4, 5, 7, 8, 9, 12, 15, 16, 18, 21, 27, 28, 30, 31, 35, 36, 39, 41, 42, 44, 45, 46, 47, 48, 57, 59, 62, 68, 77, 78, 79, 80, 82, 83, 84, 85, 86, 88, 92, 93, and 94 and the pharmaceutically acceptable salts thereof.

In another embodiment the invention relates to the group of compounds depicted in Table 1 consisting of compound number 95, 97, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 136, 137, 139, 140, 141, 142, 145, 146, 152, 153, 154, 155, 157, 158, 159, 161, 162, 163, 164, 165, 166, 167, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 184, 185, 186, 187, 188, 189, 191, 193, 194, 195, 196, 197, 198, 199, 201, 202, 203, 204, 205, 206, 207, 208, 210, 211, 212, 213, 214, 215, 216, 220, 222, 223, 224, 225, 227, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257 and the pharmaceutically acceptable salts thereof.

Unless specifically indicated, throughout the specification and the appended claims, a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers, etc.) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.

Some of the compounds of formula (I) can exist in more than one tautomeric form. The invention includes methods for using all such tautomers.

The invention includes pharmaceutically acceptable derivatives of compounds of formula (I). A "pharmaceutically acceptable derivative" refers to any pharmaceutically acceptable salt or ester,

or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound useful for the invention, or a pharmacologically active metabolite or pharmacologically active residue thereof. A pharmacologically active metabolite shall be understood to mean any compound of the invention capable of being metabolized enzymatically or chemically. This includes, for example, hydroxylated or oxidized derivative compounds of the formula (I).

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. For example, such salts include acetates, ascorbates, benzenesulfonates, benzoates, besylates, bicarbonates, bitartrates, bromides/hydrobromides, edetates, camsylates, carbonates, chlorides/hydrochlorides, citrates, edisylates, ethane disulfonates, estolates esylates, fumarates, gluceptates, gluconates, glutamates, glycolates, glycolylarsnates, hexylresorcinates, hydrabamines, hydroxymaleates, hydroxynaphthoates, iodides, isothionates, lactates, lactobionates, malates, maleates, mandelates, methanesulfonates, methylbromides, methylnitrates, methylsulfates, mucates, napsylates, nitrates, oxalates, pamoates, pantothenates, phenylacetates, phosphates/diphosphates, polygalacturonates, propionates, salicylates, stearates, subacetates, succinates, sulfamides, sulfates, tannates, tartrates, teoclates, toluenesulfonates, triethiodides, ammonium, benzathines, chloroprocaines, cholines, diethanolamines, ethylenediamines, meglumines and procaines. Further pharmaceutically acceptable salts can be formed with cations from metals like aluminium, calcium, lithium, magnesium, potassium, sodium, zinc and the like. (also see Pharmaceutical salts, Birge, S.M. et al., J. Pharm. Sci., (1977), 66, 1-19).

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.

Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention (e.g. trifluoro acetate salts) also comprise a part of the invention.

In addition, within the scope of the invention is use of prodrugs of compounds of the formula (I). Prodrugs include those compounds that, upon simple chemical transformation, are modified to produce compounds of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction. Specifically, when a prodrug is administered to a patient, the prodrug may be transformed into a compound disclosed hereinabove, thereby imparting the desired pharmacological effect.

The compounds of the invention are only those which are contemplated to be 'chemically stable' as will be appreciated by those skilled in the art. For example, a compound which would have a 'dangling valency', or a 'carbanion' are not compounds contemplated by the inventive methods disclosed herein.

For all compounds disclosed herein above in this application, in the event the nomenclature is in conflict with the structure, it shall be understood that the compound is defined by the structure.

All terms as used herein in this specification, unless otherwise stated, shall be understood in their ordinary meaning as known in the art. For example, "C₁₋₄alkyl" is a saturated aliphatic hydrocarbon monovalent radical containing 1-4 carbons such as methyl, ethyl, *n*-propyl, 1-methylethyl (isopropyl), *n*-butyl or *t*-butyl; "C₁₋₄ alkoxy" is a C₁₋₄ alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy, butoxy. All alkyl, alkenyl and alkynyl groups shall be understood as being branched or unbranched, cyclized or uncyclized where structurally possible and unless otherwise specified. Other more specific definitions are as follows:

The term "C_{1-n}-alkyl", wherein *n* is an integer from 2 to *n*, either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to *n* C atoms. For example the term C₁₋₅-alkyl embraces the radicals H₃C-, H₃C-CH₂-, H₃C-CH₂-

CH₂-, H₃C-CH(CH₃)-, H₃C-CH₂-CH₂-CH₂-, H₃C-CH₂-CH(CH₃)-, H₃C-CH(CH₃)-CH₂-, H₃C-C(CH₃)₂-, H₃C-CH₂-CH₂-CH₂-CH₂-, H₃C-CH₂-CH₂-CH(CH₃)-, H₃C-CH₂-CH(CH₃)-CH₂-, H₃C-CH(CH₃)-CH₂-CH₂-, H₃C-CH₂-C(CH₃)₂-, H₃C-C(CH₃)₂-CH₂-, H₃C-CH(CH₃)-CH(CH₃)- and H₃C-CH₂-CH(CH₂CH₃)-.

The term "C_{1-n}-alkylene" wherein n is an integer 1 to n, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 1 to n carbon atoms. For example the term C₁₋₄-alkylene includes -(CH₂)-, -(CH₂-CH₂)-, -(CH(CH₃))-, -(CH₂-CH₂-CH₂)-, -(C(CH₃)₂)-, -(CH(CH₂CH₃))-, -(CH(CH₃)-CH₂)-, -(CH₂-CH(CH₃))-, -(CH₂-CH₂-CH₂-CH₂)-, -(CH₂-CH₂-CH(CH₃))-, -(CH(CH₃)-CH₂-CH₂)-, -(CH₂-CH(CH₃)-CH₂)-, -(CH₂-C(CH₃)₂)-, -(C(CH₃)₂-CH₂)-, -(CH(CH₃)-CH(CH₃))-, -(CH₂-CH(CH₂CH₃))-, -(CH(CH₂CH₃)-CH₂)-, -(CH(CH₂CH₂CH₃))-, -(CHCH(CH₃)₂)- and -C(CH₃)(CH₂CH₃)-.

The term "C_{3-n}-cycloalkyl", wherein n is an integer 4 to n, either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms. For example the term C₃₋₇-cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

The term "heteroatom" as used herein shall be understood to mean atoms other than carbon such as O, N, S and P.

In all alkyl groups or carbon chains one or more carbon atoms can be optionally replaced by heteroatoms: O, S or N, it shall be understood that if N is not substituted then it is NH, it shall also be understood that the heteroatoms may replace either terminal carbon atoms or internal carbon atoms within a branched or unbranched carbon chain. Such groups can be substituted as herein above described by groups such as oxo to result in definitions such as but not limited to: alkoxycarbonyl, acyl, amido and thioxo.

The term "aryl" as used herein, either alone or in combination with another radical, denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to

a second 5- or 6-membered carbocyclic group which may be aromatic, saturated or unsaturated. Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl.

The term "heteroaryl" means an aromatic 5 to 6-membered monocyclic heteroaryl or an aromatic 7 to 11-membered heteroaryl bicyclic ring where at least one of the rings is aromatic, wherein the heteroaryl ring contains 1-4 heteroatoms such as N, O and S. Non-limiting examples of 5 to 6-membered monocyclic heteroaryl rings include furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, pyrrolyl, imidazolyl, tetrazolyl, triazolyl, thienyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, and purinyl. Non-limiting examples of 7 to 11-membered heteroaryl bicyclic heteroaryl rings include benzimidazolyl, quinolinyl, dihydro-2*H*-quinolinyl, isoquinolinyl, quinazolinyl, indazolyl, thieno[2,3-*d*]pyrimidinyl, indolyl, isoindolyl, benzofuranyl, benzopyranyl, benzodioxolyl, benzoxazolyl and benzothiazolyl.

The term "heterocyclyl" means a stable nonaromatic 4-8 membered monocyclic heterocyclic radical or a stable nonaromatic 6 to 11-membered fused bicyclic, bridged bicyclic or spirocyclic heterocyclic radical. The 5 to 11-membered heterocycle consists of carbon atoms and one or more, preferably from one to four heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be either saturated or partially unsaturated. Non-limiting examples of nonaromatic 4-8 membered monocyclic heterocyclic radicals include tetrahydrofuranyl, azetidiny, pyrrolidinyl, pyranyl, tetrahydropyranyl, dioxanyl, thiomorpholinyl, 1,1-dioxo-1 λ^6 -thiomorpholinyl, morpholinyl, piperidinyl, piperazinyl, and azepinyl. Non-limiting examples of nonaromatic 6 to 11-membered fused bicyclic radicals include octahydroindolyl, octahydrobenzofuranyl, and octahydrobenzothiophenyl. Non-limiting examples of nonaromatic 6 to 11-membered bridged bicyclic radicals include 2-azabicyclo[2.2.1]heptanyl, 3-azabicyclo[3.1.0]hexanyl, and 3-azabicyclo[3.2.1]octanyl. Non-limiting examples of nonaromatic 6 to 11-membered spirocyclic heterocyclic radicals include 7-aza-spiro[3,3]heptanyl, 7-spiro[3,4]octanyl, and 7-aza-spiro[3,4]octanyl. The term "heterocyclyl" or is intended to include all the possible isomeric forms.

The term "halogen" as used in the present specification shall be understood to mean bromine,

chlorine, fluorine or iodine. The definitions “halogenated”, “partially or fully halogenated”; partially or fully fluorinated; “substituted by one or more halogen atoms”, includes for example, mono, di or tri halo derivatives on one or more carbon atoms. For alkyl, a non-limiting example would be $-\text{CH}_2\text{CHF}_2$, $-\text{CF}_3$ etc.

Each alkyl, cycloalkyl, heterocycle, aryl or heteroaryl, or the analogs thereof, described herein shall be understood to be optionally partially or fully halogenated.

As used herein, “nitrogen” or N and “sulfur” or S includes any oxidized form of nitrogen and sulfur and the quaternized form of any basic nitrogen.. For example, for an $-\text{S}-\text{C}_{1-6}$ alkyl radical, unless otherwise specified, this shall be understood to include $-\text{S}(\text{O})-\text{C}_{1-6}$ alkyl and $-\text{S}(\text{O})_2-\text{C}_{1-6}$ alkyl, likewise, $-\text{S}-\text{R}_a$ may be represented as phenyl- $\text{S}(\text{O})_m-$ when R_a is phenyl and where m is 0, 1 or 2.


GENERAL SYNTHETIC METHODS

The compounds of the invention may be prepared by the general methods and examples presented below and methods known to those of ordinary skill in the art. Optimum reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Synthetic Examples section. Intermediates used in the syntheses below are either commercially available or easily prepared by methods known to those skilled in the art. Reaction progress may be monitored by conventional methods such as thin layer chromatography (TLC) or high pressure liquid chromatography-mass spec (HPLC-MS). Intermediates and products may be purified by methods known in the art, including column chromatography, HPLC, preparative TLC or recrystallization.

The methods described below and in the Synthetic Examples section may be used to prepare the compounds of formula I.

Compounds of formula I may be prepared as described in Scheme 1

Scheme 1



As illustrated above, diester **II** (R = Me or Et) and hydrazine **III** are refluxed in a suitable solvent such as ethanol with a suitable base such as potassium carbonate (K_2CO_3) yielding hydroxy pyrazole **IV**. Compound **IV** is alkylated, for example by using trimethylsilyldiazomethane in

some cases or R^1I and a suitable base such as cesium carbonate (Cs_2CO_3). Alternatively, Mitsunobu conditions are employed with ethanol to yield the desired alkoxy pyrazole chloropyridine **V** ($R^1 = Et$). Chloropyridine, **V**, is coupled with boron species, **VI**, in the presence of a palladium catalyst such as tetrakis(triphenyl)phosphine (**0**) and a suitable base such as Na_2CO_3 in aqueous 1,2-DME (1,2-dimethoxyethane) under microwave irradiation at 120 °C to provide **VII**. Alkylation of the phenol intermediate, **VII** with alkyl bromide **VIII**, where $X = Cl, I$ or Br using a base such as cesium carbonate (Cs_2CO_3) in a solvent such as acetone at about 50 °C. Subsequent deprotection of the t-Boc group with a suitable acid such as trifluoroacetic acid (TFA) provides compound **IX**. Reductive amination of amine, **IX**, with the desired ketone or aldehyde using an appropriate hydride source such as $NaBH_3CN$ in a solvent such as MeOH containing an organic acid such as AcOH at about 50 °C, followed by in situ hydrolysis with a base such as aqueous LiOH affords the desired compound of formula **I**. Alternatively, alkylations of amine, **IX** with alkyl halides in the presence of a suitable base such as cesium carbonate (Cs_2CO_3) or *N,N*-diisopropylethylamine (DIPEA) in a solvent such as MeCN (acetonitrile) followed by hydrolysis of the ester provides the desired compound of formula **I**.

UPLC/MS Methods

Retention times (RT) reported for compounds in the Synthetic Examples section are obtained by UPLC/MS using one of the following methods:

For each of the methods, the following are identical:

UPLC/MS system components- Acquity UPLC with PDA, SQ and ELS detectors.

PDA conditions- Detection: 210 to 400 nm. Sampling rate: 20pts/sec. Filter response: fast.

ELSD conditions- Gain: 1000. Sampling rate: 20pts/sec. Drift tube temp: 55° C. Nebulizer mode: cooling. Gas pressure: 41 psi.

MS conditions- Instrument: Acquity SQD with ESCi source. Ionization mode: ESI+/-.
Capillary voltage: 3.5 kV. Cone voltage: 5 V. Extractor: 1.3 V. Source temp: 150^o C.
Desolvation temp: 350^o C. Desolvation gas: 800 L/hr. Cone gas: 50 L/hr.

Conditions specific to each method are as follows

Method A1

Column- Waters BEH C18, 2.1x50mm, 1.7 um particle diameter.

Description and Gradient: Medium polar fast gradient method. ESI+/- ion mode 80-1000Da.

Gradient: 90%A to 100%B in 1.19 minutes hold at 100%B to 1.70 minutes. Flow rate 0.8mL/min. A=(95%Water 5% Acetonitrile 0.05% Formic Acid) B=(Acetonitrile 0.05% Formic Acid).

Sample Injection Volume: 1 uL

Method A2

Column- Waters BEH C18, 2.1x50mm, 1.7 um particle diameter.

Description and Gradient: Medium polar long gradient method. ESI+/- ion mode 80-1000Da.

Gradient: 90%A to 100%B in 4.45 minutes hold at 100%B to 4.58 minutes. Flow rate 0.8mL/min. A=(95%Water 5%Acetonitrile 0.05% Formic Acid) B=(Acetonitrile 0.05% Formic Acid).

Sample Injection Volume: 2 uL

Method B1

Column- CSH 2.1x50mm C18, 1.7 um particle diameter.

Description and Gradient: Medium polar fast gradient method. ESI+/- ion mode 80-1000Da.

Gradient: 90%A to 100%B in 1.19 minutes hold at 100%B to 1.70 minutes. Flow rate 0.8mL/min. A=(95%Water 5% Acetonitrile 0.05% Formic Acid) B=(Acetonitrile 0.05% Formic Acid).

Sample Injection Volume: 1 uL

Method B2

Column- CSH 2.1x50mm C18, 1.7 μ m particle diameter.

Description and Gradient: Medium polar long gradient method. ESI+/- ion mode 80-1000Da.

Gradient: 90%A to 100%B in 4.45 minutes hold at 100%B to 4.58 minutes. Flow rate 0.8mL/min. A=(95%Water 5%Acetonitrile 0.05% Formic Acid) B=(Acetonitrile 0.05% Formic Acid).


Sample Injection Volume: 2 μ L

Method A1 is used for all of the compounds except for compounds noted for which Method A2, Method B1, or Method B2 is used.

SYNTHETIC EXAMPLES

Final compounds are designated by compound numbers corresponding to the compound numbers in Table 1. Intermediates are given hyphenated numbers corresponding to the figures and numbers shown in the scheme for each example.

Example 1: Preparation of intermediate 1-[6-(2-hydroxy-3-methyl-phenyl)-pyridin-2-yl]-5-isopropoxy-1H-pyrazole-4-carboxylic acid ethyl ester (1-6)




To a round bottom flask containing EtOH (200 mL), K_2CO_3 (20.05 g, 55.720 mmol), and 1-1 (10.00 g, 69.65 mmol) is added 1-2 (13.95 mL, 69.65 mmol). The resulting mixture is refluxed

for 3 h. The reaction is cooled and the solid is collected by filtration. This solid is removed from the fritted funnel and is placed into a beaker to which is added 250 mL of 1.0 N HCl (excessive bubbling). The solution is confirmed to be acidic (pH 2) and then dichloromethane (500 mL) is added. The mixture is stirred until all solid is dissolved. The organic layer is collected, dried over MgSO_4 , and concentrated to afford **1-3** (17.18 g) as an off-white solid.

A reaction mixture of **1-3** (0.50 g, 1.87 mmol), 2-iodopropane (372.92 μL , 3.74 mmol), Cs_2CO_3 (0.91 g, 2.80 mmol) in DMA (9.0 mL) is heated at 150 $^\circ\text{C}$ in a microwave reactor for 10 min. The mixture is added to water and is extracted with EtOAc (2x). The organic layers are washed with water, brine, dried over MgSO_4 , and concentrated. The crude is purified by silica gel chromatography using a gradient of 12-100% EtOAc in heptane to yield the desired product **1-4** (0.41 g).

To a microwave vial is added **1-4** (1.00 g, 3.29 mmol), **1-5** (0.69 g, 4.52 mmol), $\text{Pd}(\text{PPh}_3)_4$ (0.37 g, 0.32 mmol), DME (15.0 mL), and 2.0 M Na_2CO_3 (4.36 mL, 8.72 mmol). The reaction mixture is heated in microwave reactor at 120 $^\circ\text{C}$ for 20 min. The reaction is extracted with dichloromethane (2x), washed with water, brine, dried over Na_2SO_4 , and concentrated. The resulting material is purified by silica gel chromatography using a gradient of 12-100% EtOAc in heptane to yield the desired product **1-6** (0.41 g).



Example 2: Preparation of intermediate 1-[6-(2-hydroxy-3-methyl-phenyl)-pyridin-2-yl]-5-methoxy-1H-pyrazole-4-carboxylic acid ethyl ester (2-8)



Intermediate **1-3** (7.00 g, 26.15 mmol) is dissolved in 1:1 mixture EtOAc/MeOH (50.0 mL). 2.0 M TMSCHN₂ in hexanes (42.70 mL, 85.40 mmol) is then added slowly via a syringe. The reaction is stirred for 3 h and is quenched by the addition of acetic acid (4.0 mL). The mixture is stirred for 10 min and then concentrated. The resulting residue is purified by silica gel chromatography using a gradient of 12-100% EtOAc in heptane to yield the desired product **2-7** (4.460 g) as an off-white solid.


To a microwave vial is added **2-7** (1.50 g, 5.33 mmol), **1-5** (0.890 g, 5.86 mmol), Pd(PPh₃)₄ (0.62 g, 0.532 mmol), DME (12.0 mL), and 2.0 M Na₂CO₃ (6.922 mL, 13.85 mmol). The reaction mixture is heated in a microwave reactor at 120 °C for 20 min. The reaction is extracted with dichloromethane (2x), washed with water, brine, dried over MgSO₄, and concentrated. The resulting material is purified by silica gel chromatography using a gradient of 12-100% EtOAc in heptane to yield the desired product **2-8** (1.17 g).

The following intermediates are synthesized in a similar fashion from the appropriate reagents:

2-9	
2-10	

2-11	
2-12	
2-13	
2-14	



Example 3: Preparation of intermediate 5-ethoxy-1-[6-(2-hydroxy-3-methylphenyl)pyridin-2-yl]-1H-pyrazole-4-carboxylic acid ethyl ester (3-15)








1-(6-Chloro-pyridin-2-yl)-5-hydroxy-1H-pyrazole-4-carboxylic acid ethyl ester, **1-3**, (3.50 g, 13.08 mmol) is dissolved in THF (90.0 mL). Triphenylphosphine (3.77 g, 14.383 mmol) and ethanol (1.14 mL, 19.614 mmol) are added and the reaction is cooled to 0 °C. The resulting suspension is slowly dissolved at 0 °C as diisopropyl azodicarboxylate (3.09 mL, 15.691 mmol) is added dropwise over 10 min. The reaction mixture is allowed to warm to ambient temperature and is stirred for 16 h. The reaction is concentrated in vacuo and the residue is dissolved in a minimal amount of dichloromethane and subjected to silica gel chromatography using a gradient of 3-50% EtOAc in heptane to yield the desired product **3-14** (3.33 g).

To a microwave vial is added **3-14** (250.0 mg, 0.85 mmol), **1-5** (134.9 mg, 0.89 mmol), Pd(PPh₃)₄ (60.05 mg, 0.05 mmol), DME (5.0 mL), and 2.0 M Na₂CO₃ (1.06 mL, 2.11 mmol). The reaction mixture is heated in a microwave reactor at 120 °C for 20 min. The reaction is extracted with dichloromethane (2x), washed with water, brine, dried over MgSO₄, and concentrated. The resulting material is purified by silica gel chromatography using a gradient of 12-100% EtOAc in heptane to yield the desired product, **3-15** (227.0 mg).


The following intermediate is synthesized in a similar fashion from the appropriate reagents:

3-16	
3-17	

3-18	
3-19	
3-20	
3-21	
3-22	

3-23	
3-24	

Example 4: Preparation of intermediate 6-bromomethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (4-19)



Compound **4-17** (12.50 g, 45.08 mmol) is dissolved in dry THF (125.0 mL) under nitrogen at 25 °C. Borane THF complex (99.17 mL, 99.17 mmol) is added via syringe and the mixture is stirred at 25 °C for 16 h. Water (10.0 mL) is slowly added and then 2.0 M Na₂CO₃ (15.0 mL). This mixture is stirred for 15 min and then is diluted with EtOAc and the organic layers are collected. The organics are rinsed with 1.0 M HCl, dried over MgSO₄, and concentrated in vacuo to afford an oil. The oil is purified by silica gel chromatography using a gradient of 10-80% EtOAc in heptane to yield the desired product, **4-18** (11.78 g), as a white solid.


To a solution of alcohol, **4-18**, (9.50 g, 36.08 mmol) and N,N-diisopropylethylamine (9.43 mL, 54.11 mmol) in dichloromethane (200.0 mL) is added triphenylphosphine dibromide (23.79 g, 54.11 mmol) at 0 °C. The reaction is stirred for 1 h and concentrated in vacuo. The resulting

residue is purified by silica gel chromatography using a gradient of 7-60% EtOAc in heptanes to yield the desired product, **4-19** (8.74 g), as a white solid.

The following intermediates are synthesized in similar fashion from the appropriate reagents:

4-20	
4-21	
4-22	
4-23	
4-24	

Example 5: Preparation of intermediate 6-bromomethyl-5-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (5-34)



A solution of acid **5-23** (350.0 g, 2.10 mol) in THF (1.4 L) is added to a slurry of LAH (95.9 g, 1.40 mol) in THF (2.5 L) at 0°C . The mixture is stirred at room temperature for 0.5 h, then heated to reflux for 1 h. The mixture is then cooled to 0°C , and slowly quenched by the addition of saturated aqueous ammonium chloride solution. A large excess of solid Na_2SO_4 and EtOAc are added, then the solids are collected by filtration. The filtrate is concentrated in vacuo to afford crude **5-24** (350.0 g) which is used directly in the next step.

To a solution of compound **5-24** (294.0 g, 1.90 mol) in dichloromethane (2.2 L) at -10°C is added thionyl chloride (SOCl_2) (460.0 g, 3.90 mol). Then the reaction mixture is heated to reflux for 1 h, followed by concentration in vacuo to provide crude **5-25** (298.0 g) which is used directly in the next step.

A mixture of compound **5-25** (298.0 g, 1.8 mol) and NaCN (154.5 g, 2.1 mol) in DMF (1.2 L) is stirred at room temperature for 12 h, then extracted with EtOAc and H₂O. The organic layer is dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue is purified by silica gel chromatography (petroleum ether:EtOAc = 50:1) to deliver intermediate **5-26** (230.0 g).

A mixture of compound **5-26** (180.0 g, 1.10 mol), Raney Ni (40.0 g) and aqueous ammonia (250.0 mL) in MeOH (1.0 L) is stirred under H₂ (50 psi) at room temperature for 5 h. The mixture is then filtered and concentrated to give compound **5-27** (165.0 g) that is used directly in the next step.

A solution of compound **5-27** (165.0 g, 1.0 mol) and aqueous formaldehyde (HCHO) (37 wt%, 30 g, 1.0 mol) in formic acid (HCO₂H) (1.5 L) is stirred at 50 °C overnight, then the solvent is removed in vacuo to afford compound **5-28** (150.0 g) which is used directly in the next step.

Compound **5-28** (150.0 g, 847 mmol) is suspended in aqueous HBr (48%, 1.0 L), then heated to 100 °C overnight. Removal of the solvent in vacuo provides compound **5-29** (195.0 g) which is used directly in the next step.

To a solution of compound **5-29** (195.0 g, 799 mmol) in THF (1.0 L) and H₂O (1.0 L) is added Et₃N (242.0 g, 2.4 mol) and Boc₂O (174.0 g, 799 mmol). The resulting mixture is stirred at room temperature overnight, then extracted with EtOAc. The combined organic phases are washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude product is purified by silica gel chromatography (using 10:1 petroleum ether:EtOAc) to provide compound **5-30** (100.0 g).

To a solution of compound **5-30** (100.0 g, 380 mmol) and Et₃N (76.8 g, 760 mmol) in dichloromethane (1.5 L) cooled to 0 °C is added triflic anhydride (Tf₂O) (107.0 g, 380 mmol) via addition funnel. Upon complete addition of Tf₂O, the solution is warmed to room temperature for 5 h. The reaction mixture is then treated with H₂O and dichloromethane, and the organic phase is separated, washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo.


The residue is purified by silica gel chromatography (using 20:1 petroleum ether:EtOAc) to provide compound **5-31** (105.0 g).

Compound **5-31** (50.0 g, 127 mmol) is combined with palladium (II) acetate ($\text{Pd}(\text{OAc})_2$) (5.0 g), dppp (5.0 g) and Et_3N (25.7 g, 254 mmol) in EtOH (1.0 L), then stirred at 80 °C overnight under CO at a pressure of 4 MPa. The mixture is cooled to room temperature, then the solids are removed by filtration. The filtrate is concentrated in vacuo, and the remaining residue is purified by silica gel chromatography (using 20:1 petroleum ether:EtOAc) to provide compound **5-32** (25.0 g).

To a solution of LAH (12.5 g, 330 mmol) in THF (400 mL) cooled to -30°C is added dropwise a solution of compound **5-32** (35.0 g, 110 mmol) in THF (400 mL) over 30 min. After addition, the reaction mixture is stirred at 0°C for 30 min, then treated with H_2O and dichloromethane. The organic phase is separated, washed with brine, dried over Na_2SO_4 , filtered, and concentrated in vacuo. The crude product is purified by silica gel chromatography (using 10:1 petroleum ether:EtOAc) to provide the desired intermediate **5-33** (21.1 g).

To a solution of alcohol, **5-33**, (6.00 g, 21.63 mmol) and N,N-diisopropylethylamine (5.65 mL, 32.45 mmol) in dichloromethane (200.0 mL) is added triphenylphosphine dibromide (14.27 g, 32.45 mmol) at 0 °C. The reaction is stirred for 1 h and concentrated in vacuo. The resulting residue is purified by silica gel chromatography using a gradient of 7-60% EtOAc in heptanes to yield the desired product, **5-34** (6.60 g), as a white solid.

Example 6: Preparation of intermediate 6-Bromomethyl-5-chloro-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (6-39)




To a solution of N,N,N'-trimethyl-ethane-1,2-diamine (45.0 g, 442.0 mmol) in THF (500 mL) is added a solution of n-BuLi (177.0 mL, 442 mmol) at -40 °C under N₂. The mixture is stirred at -40 °C for 30 min. After the mixture is cooled to -70 °C, compound **6-35** (50.0 g, 368 mmol) in THF (250 mL) is added to the reaction mixture. The mixture is allowed to warm to 0 °C and stirred for 30 min. Then the reaction mixture is cooled to -78 °C and n-BuLi (177.0 mL, 442 mmol) is added. The mixture is allowed to warm to 10 °C and is cooled to -30 °C before it is added to a solution of C₂Cl₆ (287.0 g, 1.1 mol) in THF (600 mL). The mixture is stirred 2 h at room temperature. The reaction mixture is poured into 1000 mL of 10% HCl solution and extracted with EtOAc. The organic layers are washed with brine, dried over Na₂SO₄, concentrated, and purified by silica gel chromatography to give compound **6-36** (36.7 g).

To a solution of compound **6-36** (105.0 g, 615 mmol) in HOAc (700 mL) is added NH₄OAc (47.4 g, 615 mmol) at room temperature under N₂. To this reaction mixture is added MeNO₂ (188.0 g, 3.08 mol) and the mixture is warmed to 40 °C for 12 h and then is stirred at 85 °C for 6 h. TLC showed the reaction is completed. The mixture is quenched with H₂O and is extracted with dichloromethane. The organic layers are washed with brine, dried over Na₂SO₄, concentrated, and purified by silica gel chromatography to give compound **6-37** (97.5 g).


To a solution of compound **6-37** (48.0 g, 225 mmol) in THF (900 mL) is added LAH (34.1 g, 899 mol) at -20 °C. The mixture is stirred at room temperature for 5 h and 50 °C for 30 min. The mixture is quenched with H₂O and is extracted with dichloromethane. The organic layers

are washed with brine, dried over Na₂SO₄, and concentrated to give compound **6-38** (28.0 g) which is used directly in the next step.

The following compound is prepared from intermediate **6-38** according to the procedure described in Example 5:



Example 7: Preparation of 5-isopropoxy-1-(6-{3-methyl-2-[2-(tetrahydro-pyran-4-yl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-phenyl}-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (1**)**



Intermediate **1-6** (373.0 mg, 0.88 mmol), bromide **4-19** (287.1 mg, 0.88 mmol) and Cs₂CO₃ (573.5 mg, 1.76 mmol) are combined in acetone (11.0 mL) and heated to 50 °C for 5 h. The reaction mixture is extracted with EtOAc, washed with brine, dried over MgSO₄, and concentrated. The resulting material is purified by silica gel chromatography (using a gradient of 5-100% EtOAc/heptane) to provide the desired intermediate, **7-40** (502.0 mg).

The carbamate, **7-40**, (496.0 mg, 0.79 mmol) is dissolved in dichloromethane (4.0 mL) and treated with TFA (1.0 mL) at room temperature. After 1 h the mixture is neutralized with

saturated NaHCO₃ solution and the layers are separated with a hydrophobic frit. The organic filtrate is concentrated to afford **7-41** (375.0 mg).

Amine **7-41** (98.0 mg, 0.19 mmol) is combined with 4Å molecular sieves (30 mg), tetrahydropyran 4-one (28 µL, 0.28 mmol), AcOH (20 µL), and Na(CN)BH₃ (24 mg, 0.38 mmol) in MeOH (4 mL). The mixture is stirred at room temperature for 30 min, and then heated to 50 °C for 12 h. The mixture is diluted with THF (1.0 mL) and water (1 mL). To this is added LiOH (42.8 mg, 1.86 mmol) and the reaction is heated to 50 °C for 2 h. It is then concentrated under N₂, triturated with 1:1 MeOH/DMSO, filtered through a 0.45 micron syringe filter, and the filtrate is purified by gradient elution (10-100% MeCN/water + 0.1% HCO₂H) on a Gilson RP-HPLC. Concentrated in vacuo to afford title compound **1** (64.0 mg). MS, electrospray, m/z = 583.3 [M+H], RT 0.71 min.

Example 7A: Procedure is equivalent to Example 7, however during reductive amination step Na(OAc)₃BH in dichloromethane is substituted for NaCNBH₃/AcOH/MeOH.

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using the appropriate starting materials and purification conditions:

Compound **2**: MS, electrospray, m/z = 617.3 [M+H], RT 0.79 min;

Compound **37**: MS, electrospray, m/z = 541.3 [M+H], RT 0.75 min;

Compound **38**: MS, electrospray, m/z = 571.4 [M+H], RT 0.76 min;

Compound **39**: MS, electrospray, m/z = 555.3 [M+H], RT 0.73 min;

Compound **40**: MS, electrospray, m/z = 583.3 [M+H], RT 0.73 min;

Compound **41**: MS, electrospray, m/z = 569.3 [M+H], RT 0.73 min;

Compound **42**: MS, electrospray, m/z = 583.3 [M+H], RT 0.75 min;

Compound **109**: MS, electrospray, m/z = 569.4 [M+H], RT 0.77 min;

Resolution: ChiralPak AD-H Prep 40% i-Propanol(1% iPrNH₂):CO₂ @ 80 ml/min., 100 bar, 25°C

Compound **111**: MS, electrospray, m/z = 569.4 [M+H], RT 0.77 min;

Resolution: ChiralPak AD-H Prep 40% i-Propanol(1% iPrNH₂):CO₂ @ 80 ml/min., 100 bar, 25°C

Compound **113**: MS, electrospray, m/z = 583.3 [M+H], RT 0.75 min;

Resolution: Lux Cellulose 2 Prep 60% MeOH(1% iPrNH₂):CO₂ @ 55 ml/min., 100 bar, 25°C

Compound **115**: MS, electrospray, m/z = 583.3 [M+H], RT 0.75 min;

Resolution: Lux Cellulose 2 Prep 60% MeOH(1% iPrNH₂):CO₂ @ 55 ml/min., 100 bar, 25°C

Compound **144**: MS, electrospray, m/z = 569.4 [M+H], RT 0.77 min.

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **1-6**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **43**: MS, electrospray, m/z = 555.4 [M+H], RT 0.77 min;

Compound **44**: MS, electrospray, m/z = 585.4 [M+H], RT 0.80 min;

Compound **45**: MS, electrospray, m/z = 569.3 [M+H], RT 0.75 min;

Compound **46**: MS, electrospray, m/z = 597.4 [M+H], RT 0.76 min;

Compound **47**: MS, electrospray, m/z = 583.3 [M+H], RT 0.76 min;

Compound **48**: MS, electrospray, m/z = 597.4 [M+H], RT 0.77 min;

Compound **104**: MS, electrospray, m/z = 597.5 [M+H], RT 0.80 min;

Compound **116**: MS, electrospray, m/z = 597.4 [M+H], RT 0.77 min;

Resolution: Lux Cellulose 2 Prep 65% MeOH(1% iPrNH₂):CO₂ @ 60 ml/min., 125 bar, 25°C

Compound **117**: MS, electrospray, m/z = 597.4 [M+H], RT 0.77 min;

Resolution: Lux Cellulose 2 Prep 65% MeOH(1% iPrNH₂):CO₂ @ 60 ml/min., 125 bar, 25°C

Compound **122**: MS, electrospray, m/z = 581.5 [M+H], RT 0.72 min;

Resolution: RegisPack Prep 15% IPA(1% diethylamine): CO₂ @ 12 ml/min., 120 bar, 40°C

Compound **123**: MS, electrospray, m/z = 581.5 [M+H], RT 0.72 min.

Resolution: RegisPack Prep 15% IPA(1% diethylamine): CO₂ @ 12 ml/min., 120 bar, 40°C

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **2-8**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **3**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.64 min;
Compound **5**: MS, electrospray, $m/z = 587.2$ [M-H], RT 0.78 min;
Compound **8**: MS, electrospray, $m/z = 527.2$ [M+H], RT 0.69 min;
Compound **12**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.68 min;
Compound **13**: MS, electrospray, $m/z = 513.2$ [M+H], RT 0.70 min;
Compound **14**: MS, electrospray, $m/z = 541.3$ [M+H], RT 0.77 min;
Compound **15**: MS, electrospray, $m/z = 541.2$ [M+H], RT 0.68 min;
Compound **23**: MS, electrospray, $m/z = 543.3$ [M+H], RT 0.70 min;
Compound **24**: MS, electrospray, $m/z = 525.2$ [M+H], RT 0.72 min;
Compound **25**: MS, electrospray, $m/z = 539.3$ [M+H], RT 0.75 min;
Compound **61**: MS, electrospray, $m/z = 583.3$ [M+H], RT 0.72 min;
Compound **62**: MS, electrospray, $m/z = 583.4$ [M+H], RT 0.72 min;
Compound **73**: MS, electrospray, $m/z = 611.4$ [M+H], RT 0.75 min;
Compound **75**: MS, electrospray, $m/z = 593.4$ [M-H], RT 0.72 min;
Compound **81**: MS, electrospray, $m/z = 585.1$ [M+H], Method A2, RT 1.42 min;
Compound **86**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.78 min;
Compound **87**: MS, electrospray, $m/z = 581.4$ [M+H], RT 0.80 min;
Compound **90**: MS, electrospray, $m/z = 583.4$ [M+H], RT 0.80 min;
Compound **91**: MS, electrospray, $m/z = 583.4$ [M+H], RT 0.83 min;
Compound **92**: MS, electrospray, $m/z = 571.4$ [M+H], RT 0.79 min;
Compound **102**: MS, electrospray, $m/z = 609.4$ [M+H], RT 0.83 min;
Compound **103**: MS, electrospray, $m/z = 609.4$ [M+H], RT 0.89 min;
Compound **188**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.58 min;
Compound **192**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.58 min.

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **2-8**, bromide, **4-20**, and other appropriate starting materials and purification conditions:

Compound **10**: MS, electrospray, $m/z = 555.2$ [M+H], RT 0.82 min;

Compound **89**: MS, electrospray, $m/z = 583.4$ [M+H], Method A2, RT 1.80 min.

The following compounds from Table 1 are prepared according to the procedure described in Example **7a**, using phenol, **2-8**, bromide, **4-20**, and other appropriate starting materials and purification conditions:

Compound **217**: MS, electrospray, $m/z = 569.3$ [M+H], 1.45 min (method B2);

Compound **218**: MS, electrospray, $m/z = 583.3$ [M+H], 1.52 min (method B2);

Compound **219**: MS, electrospray, $m/z = 599.3$ [M+H], 1.46 min (method B2);

The following compounds from Table 1 are prepared according to the procedure described in Example **7**, using phenol, **2-8**, bromide, **4-21**, and other appropriate starting materials and purification conditions:

Compound **59**: MS, electrospray, $m/z = 541.3$ [M+H], RT 0.66 min;

Compound **85**: MS, electrospray, $m/z = 513.2$ [M+H], RT 0.71 min.

The following compound from Table 1 is prepared according to the procedure described in Example **7**, using phenol, **2-8**, bromide, **4-22**, and other appropriate starting materials and purification conditions:

Compound **100**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.77 min.

The following compound from Table 1 is prepared according to the procedure described in Example **7**, using phenol, **2-8**, bromide, **4-23**, and other appropriate starting materials and purification conditions:

Compound **130**: MS, electrospray, $m/z = 571.4$ [M+H], RT 0.69 min (Method B1);

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **2-8**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **16**: MS, electrospray, $m/z = 541.2$ [M+H], RT 0.70 min;

Compound **27**: MS, electrospray, $m/z = 569.3$ [M+H], RT 0.70 min;

Compound **28**: MS, electrospray, $m/z = 569.3$ [M+H], RT 0.70 min;

Compound **30**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.77 min;

Compound **31**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.70 min.

The following compounds from Table 1 are prepared according to the procedure described in Example 7a, using phenol, **2-8**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **105**: MS, electrospray, $m/z = 555.4$ [M+H], RT 0.72 min

Resolution: Chirapak AD-H, 20x250mm; MeOH to 30 mg/mL, 35% EtOH (1% DEA) in heptane over 18 min, ambient temp. and collection at 290nm;

Compound **106**: MS, electrospray, $m/z = 555.4$ [M+H], RT 0.72 min

Resolution: Chirapak AD-H, 20x250mm; MeOH to 30 mg/mL, 35% EtOH (1% DEA) in heptane over 18 min, ambient temp. and collection at 290nm;

Compound **127**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.76 min;

Compound **139**: MS, electrospray, $m/z = 585.4$ [M+H], RT 0.74 min

Resolution: Chiracel OD-H, 20x250mm; 10%MeOH in CO₂ at 55.5g/min over 28 min, 140 Bar, 40°C and collection at 254 nm;

Compound **140**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.74 min

Resolution: Chiracel OD-H, 20x250mm; 10%MeOH in CO₂ at 58g/min over 30 min, 120 Bar, 40°C and collection at 254 nm;

Compound **141**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.74 min

Resolution: Chiracel OD-H, 20x250mm; 10%MeOH in CO₂ at 58g/min over 30 min, 120 Bar, 40°C and collection at 254 nm;

Compound **142**: MS, electrospray, $m/z = 585.4$ [M+H], RT 0.74 min

Resolution: Chiracel OD-H, 20x250mm; 10%MeOH in CO₂ at 55.5g/min over 28 min, 140 Bar, 40°C and collection at 254 nm;

Compound **191**: MS, electrospray, m/z = 569.3 [M+H], RT 0.61 min;

Compound **198**: MS, electrospray, m/z = 583.3 [M+H], RT 0.66 min (method B1);

Resolution: LUX Amylose-2, 21x250mm 35% (1:1:1MeOH:EtOH:iPA)+Et₂NH:CO₂, 80ml/min, 110bar, 40°C

Compound **199**: MS, electrospray, m/z = 583.3 [M+H], RT 0.66 min (method B1).

Resolution: LUX Amylose-2, 21x250mm 35% (1:1:1MeOH:EtOH:iPA)+Et₂NH:CO₂, 80ml/min, 110bar, 40°C

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **2-8**, bromide, **6-39**, and other appropriate starting materials and purification conditions:

Compound **17**: MS, electrospray, m/z = 561.2 [M+H], RT 0.77 min;

Compound **18**: MS, electrospray, m/z = 589.3 [M+H], RT 0.73 min;

Compound **19**: MS, electrospray, m/z = 589.3 [M+H], RT 0.73 min;

Compound **20**: MS, electrospray, m/z = 559.3 [M+H], RT 0.76 min;

Compound **21**: MS, electrospray, m/z = 575.3 [M+H], RT 0.83 min;

Compound **22**: MS, electrospray, m/z = 575.3 [M+H], RT 0.73 min.

The following compound from Table 1 is prepared according to the procedure described in Example 7, using phenol, **2-9**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **7**: MS, electrospray, m/z = 547.2 [M+H], RT 0.71 min.

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **2-10**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **9**: MS, electrospray, $m/z = 581.2$ [M+H], RT 0.73 min;

Compound **83**: MS, electrospray, $m/z = 609.4$ [M+H], RT 0.79 min.

The following compound from Table 1 is prepared according to the procedure described in Example 7, using phenol, **2-10**, bromide, **4-21**, and other appropriate starting materials and purification conditions:

Compound **93**: MS, electrospray, $m/z = 595.3$ [M+H], RT 0.80 min.

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **2-10**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **84**: MS, electrospray, $m/z = 623.4$ [M+H], RT 0.83 min;

Compound **88**: MS, electrospray, $m/z = 595.3$ [M+H], RT 0.80 min;

Compound **107**: MS, electrospray, $m/z = 607.4$ [M+H], RT 0.77 min;

Resolution: Chirapak AD-H, 30x250mm; 50%Isopropanol:Hexane with 1% Isopropylamine @ 88 mL/min, 100 bar CO₂, ambient temp.

Compound **108**: MS, electrospray, $m/z = 607.4$ [M+H], RT 0.77 min.

Resolution: Chirapak AD-H, 30x250mm; 50%Isopropanol:Hexane with 1% Isopropylamine @ 88 mL/min, 100 bar CO₂, ambient temp.

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **2-11**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **52**: MS, electrospray, $m/z = 547.3$ [M-H], RT 0.70 min;

Compound **53**: MS, electrospray, $m/z = 575.3$ [M-H], RT 0.71 min.

The following compound from Table 1 is prepared according to the procedure described in Example 7, using phenol, **2-12**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **63**: MS, electrospray, $m/z = 559.3$ [M+H], RT 0.65 min.

The following compound from Table 1 is prepared according to the procedure described in Example 7, using phenol, **2-13**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **98**: MS, electrospray, $m/z = 555.4$ [M+H], RT 0.76 min.

The following compound from Table 1 is prepared according to the procedure described in Example 7, using phenol, **2-13**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **99**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.79 min.

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, **2-14**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **124**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.71 min

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **3-15**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **6**: MS, electrospray, $m/z = 541.2$ [M+H], RT 0.73 min;

Compound **32**: MS, electrospray, $m/z = 527.3$ [M+H], RT 0.73 min;

Compound **34**: MS, electrospray, $m/z = 569.3$ [M+H], RT 0.71 min;

Compound **35**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.71 min;
Compound **36**: MS, electrospray, $m/z = 569.3$ [M+H], RT 0.73 min;
Compound **110**: MS, electrospray, $m/z = 555.4$ [M+H], RT 0.75 min;
Resolution: ChiralPak AD-H Prep 30% EtOH:CO₂ @ 80 ml/min., 100 bar, 25°C
Compound **112**: MS, electrospray, $m/z = 555.4$ [M+H], RT 0.75 min.
Resolution: ChiralPak AD-H Prep 30% EtOH:CO₂ @ 80 ml/min., 100 bar, 25°C

The following compound from Table 1 is prepared according to the procedure described in Example 7, using phenol, **3-15**, bromide, **4-22**, and other appropriate starting materials and purification conditions:

Compound **245**: MS, electrospray, $m/z = 583.1$ [M+H], RT 0.62 min.

The following compound from Table 1 is prepared according to the procedure described in Example 7, using phenol, **3-15**, bromide, **4-23**, and other appropriate starting materials and purification conditions:

Compound **131**: MS, electrospray, $m/z = 585.4$ [M+H], RT 1.21 min (Method B1);

The following compound from Table 1 is prepared according to the procedure described in Example 7, using phenol, **3-15**, bromide, **4-24**, and other appropriate starting materials and purification conditions:

Compound **205**: MS, electrospray, $m/z = 583.3$ [M+H], RT 0.67 min (Method B1);

Compound **213**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.67 min (Method B1);

The following compounds from Table 1 are prepared according to the procedure described in Example 7, using phenol, **3-15**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **114**: MS, electrospray, $m/z = 583.5$ [M+H], RT 0.62 min;

Compound **125**: MS, electrospray, $m/z = 569.4$ [M+H], RT 1.25 min (Method B2);
Resolution: LUX 5u Cellulose 2 Prep, 23% MeOH (1% Et₂NH) in CO₂ at 78ml/min over 21 minutes, 160 Bar, 40°C.

Compound **126**: MS, electrospray, $m/z = 569.4$ [M+H], RT 1.25 min (Method B2);
Resolution: LUX 5u Cellulose 2 Prep, 23% MeOH (1% Et₂NH) in CO₂ at 78ml/min over 21 minutes, 160 Bar, 40°C.

Compound **128**: MS, electrospray, $m/z = 583.5$ [M+H], RT 1.31 min (Method B2);
Resolution: Chiralcel OD-H, 20x250mm 5.8% MeOH (~1% Et₂NH) in CO₂ at 85g/min, 160 Bar, 40°C.

Compound **129**: MS, electrospray, $m/z = 583.5$ [M+H], RT 1.31 min (Method B2);
Resolution: Chiralcel OD-H, 20x250mm 5.8% MeOH (~1% Et₂NH) in CO₂ at 85g/min, 160 Bar, 40°C.

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-15**, bromide, **4-23**, and other appropriate starting materials and purification conditions:

Compound **216**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.64 min (Method B1);

Compound **247**: MS, electrospray, $m/z = 557.1$ [M+H], RT 1.21 min (Method B2);

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-15**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **146**: MS, electrospray, $m/z = 597.4$ [M+H], RT 0.65 min (Method B1);

Compound **152**: MS, electrospray, $m/z = 597.4$ [M+H], RT 0.65 min (Method B1);

Resolution: Chiralcel OD-H, 20x250mm 5.8% MeOH (~1% Et₂NH) in CO₂ at 85g/min, 160 Bar, 40°C;

Compound **153**: MS, electrospray, $m/z = 597.4$ [M+H], RT 0.65 min (Method B1);

Resolution: Chiralcel OD-H, 20x250mm 5.8% MeOH (~1% Et₂NH) in CO₂ at 85g/min, 160 Bar, 40°C;

Compound **155**: MS, electrospray, $m/z = 613.4$ [M+H], RT 0.55 min (Method B1);
Compound **156**: MS, electrospray, $m/z = 573.4$ [M+H], RT 0.43 min (Method B1);
Compound **163**: MS, electrospray, $m/z = 625.3$ [M+H], RT 0.77 min;
Compound **164**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.71 min;
Compound **172**: MS, electrospray, $m/z = 597.3$ [M+H], RT 1.31 min (Method B2);
Compound **179**: MS, electrospray, $m/z = 613.1$ [M+H], RT 0.67 min (Method B1);
Compound **189**: MS, electrospray, $m/z = 583.5$ [M+H], RT 0.63 min
Compound **193**: MS, electrospray, $m/z = 583.51$ [M+H], RT 0.63 min
Compound **208**: MS, electrospray, $m/z = 587.3$ [M+H], RT 1.48 min (Method B2);
Compound **236**: MS, electrospray, $m/z = 597.3$ [M+H], RT 1.54 min (Method A2);
Resolution: LUX 5u Cellulose 1 Prep 7% EtOH:Heptane @ 10ml/min
Compound **238**: MS, electrospray, $m/z = 569.2$ [M+H], RT 0.60 min;

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-17**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **135**: MS, electrospray, $m/z = 611.5$ [M+H], RT 0.86 min;
Compound **136**: MS, electrospray, $m/z = 611.5$ [M+H], RT 0.83 min;
Compound **137**: MS, electrospray, $m/z = 597.5$ [M+H], RT 0.84 min;

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-18**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **148**: MS, electrospray, $m/z = 609.4$ [M+H], RT 0.81 min;

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-19**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **133**: MS, electrospray, $m/z = 597.5$ [M+H], RT 0.81 min.

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-20**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **134**: MS, electrospray, $m/z = 611.5$ [M+H], RT 0.85 min;

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-21**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **149**: MS, electrospray, $m/z = 613.3$ [M+H], RT 0.74 min;

Compound **150**: MS, electrospray, $m/z = 599.5$ [M+H], RT 0.72 min;

Compound **151**: MS, electrospray, $m/z = 613.3$ [M+H], RT 0.74 min;

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-22**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **183**: MS, electrospray, $m/z = 573.1$ [M+H], RT 0.53 min.

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-22**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **182**: MS, electrospray, $m/z = 585.9$ [M+H], RT 0.55 min.

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-22**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **181**: MS, electrospray, $m/z = 570.7$ [M+H], RT 0.61 min.

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-22**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **180**: MS, electrospray, $m/z = 583.7$ [M+H], RT 0.64 min.


The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-22**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **209**: MS, electrospray, $m/z = 541.4$ [M+H], RT 0.52 min.

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-22**, bromide, **5-34**, and other appropriate starting materials and purification conditions:

Compound **224**: MS, electrospray, $m/z = 556.7$ [M+H], RT 0.52 min.

Example 8: Preparation of 5-ethoxy-1-(6-{2-[2-(2-fluoro-1-methyl-ethyl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-3-methyl-phenyl}-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (49)



Amine, **8-42** (2.94 g, 5.74 mmol) is dissolved in methanol (20 mL), THF (20 mL) and water (10 mL). To this solution is added LiOH (0.971 g, 40.60 mmol) and the mixture is heated at 50 °C for 2 h. The reaction is cooled to room temperature and concentrated in vacuo. The crude product is purified by reverse phase column chromatography on C18 (using a solvent gradient of 5- 95% MeCN/H₂O + 0.1% TFA) to provide **60** (2.94 g). MS, electrospray, *m/z* = 485.1 [M+H], RT 0.68 min).

Amino acid **60** (78.0 mg, 0.15 mmol) is combined with 4Å molecular sieves (20 mg), 1-fluoropropan-2-one (100 µL), AcOH (25.0 µL), and Na(CN)BH₃ (29.2 mg, 0.44 mmol) in MeOH (4 mL). The mixture is stirred at room temperature for 30 min and then heated to 50 °C for 12 h. It is then concentrated under N₂, triturated with 1:1 MeOH/DMSO, filtered through a 0.45 micron syringe filter, and the filtrate is purified by gradient elution (10-100% MeCN/water + 0.1% HCO₂H) on a Gilson RP-HPLC. Concentrated in vacuo to afford title compound **49** (70.0 mg). MS, electrospray, *m/z* = 545.3 [M+H], RT 0.72 min.

The following compounds from Table 1 are prepared according to the procedure described in Example 8, using appropriate starting materials and purification conditions:

Compound **64**: MS, electrospray, *m/z* = 583.4 [M+H], RT 0.70 min;
 Compound **65**: MS, electrospray, *m/z* = 597.4 [M+H], RT 0.75 min;
 Compound **66**: MS, electrospray, *m/z* = 597.4 [M+H], RT 0.72 min;
 Compound **67**: MS, electrospray, *m/z* = 625.5 [M+H], RT 0.78 min;
 Compound **68**: MS, electrospray, *m/z* = 569.4 [M+H], RT 0.68 min;

Compound **69**: MS, electrospray, $m/z = 583.4$ [M+H], RT 0.70 min;
 Compound **70**: MS, electrospray, $m/z = 605.4$ [M+H], RT 0.71 min;
 Compound **71**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.71 min;
 Compound **76**: MS, electrospray, $m/z = 597.4$ [M+H], RT 0.79 min;
 Compound **77**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.69 min;
 Compound **78**: MS, electrospray, $m/z = 583.4$ [M+H], RT 0.71 min;
 Compound **79**: MS, electrospray, $m/z = 597.4$ [M+H], RT 0.75 min;
 Compound **80**: MS, electrospray, $m/z = 611.4$ [M+H], RT 0.74 min;
 Compound **94**: MS, electrospray, $m/z = 587.4$ [M+H], RT 0.80 min;
 Compound **95**: MS, electrospray, $m/z = 597.4$ [M+H], RT 0.82 min.

The following compounds from Table 1 are prepared according to the procedure described in Example 8, using phenol, **3-16**, bromide, **4-19**, and other appropriate starting materials and purification conditions:

Compound **50**: MS, electrospray, $m/z = 505.2$ [M+H], RT 0.66 min;
 Compound **51**: MS, electrospray, $m/z = 561.3$ [M+H], RT 0.70min;
 Compound **54**: MS, electrospray, $m/z = 589.3$ [M+H], RT 0.72 min;
 Compound **55**: MS, electrospray, $m/z = 575.2$ [M+H], RT 0.71 min;
 Compound **56**: MS, electrospray, $m/z = 563.3$ [M+H], RT 0.74 min;
 Compound **57**: MS, electrospray, $m/z = 623.3$ [M+H], RT 0.80 min;
 Compound **58**: MS, electrospray, $m/z = 563.2$ [M+H], RT 0.76 min.


Example 9: Preparation of intermediate 3,3-difluoro-cyclobutanecarbaldehyde (9-44)



Dess-Martin periodinane (2.6 g, 6.1 mmol) is added to a mixture of 3,3-difluorocyclobutylmethanol, **9-43**, (0.5 g, 4.0 mmol) and NaHCO₃ (1.4 g, 16.0 mmol) in dichloromethane (10 mL) at room temperature. The resulting slurry is stirred in the dark for 15 h

and then poured into a solution of saturated aqueous NaHCO_3 . The resulting mixture is filtered through a hydrophobic frit with excess dichloromethane. The organic filtrate is washed with saturated aqueous $\text{Na}_2\text{S}_2\text{O}_5$, and then separated with another hydrophobic frit. The filtrate is dried over MgSO_4 , and then filtered through a pad of diatomaceous earth using dichloromethane. All but about 5 mL of dichloromethane is removed by short path distillation at atmospheric pressure (50 °C bath temperature). The remaining solution is cooled to -78 °C for 15 min to precipitate residual periodinane solids. The solvent is removed by syringe and passed through a 0.45 micron Millipore filter. The filtrate containing the crude aldehyde **9-44** (~0.1M in dichloromethane) is used as is without further purification or concentration.

Example 10: Preparation of 1-(6-{2-[2-(3,3-difluoro-cyclobutylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-3-methyl-phenyl}-pyridin-2-yl)-5-isopropoxy-1H-pyrazole-4-carboxylic acid (4**)**



Amine **7-41** (56.0 mg, 0.11 mmol) is combined with 4Å molecular sieves (20 mg), 3,3-difluorocyclobutanecarboxaldehyde, **9-44**, (100 μL , 0.21 mmol), AcOH (20 μL), and $\text{Na}(\text{CN})\text{BH}_3$ (20.01 mg, 0.32 mmol) in MeOH (2.0 mL). The mixture is stirred at room temperature for 30 min, and then heated to 50 °C for 12 h. The mixture is diluted with THF (1.0 mL) and water (1.0 mL). To this is added LiOH (14.68 mg, 0.64 mmol) and the reaction is heated to 50 °C for 2 h. It is then concentrated under N_2 , triturated with 1:1 MeOH/DMSO, filtered through a 0.45 micron syringe filter, and the filtrate is purified by gradient elution (10-100% MeCN/water + 0.1% HCO_2H) on a Gilson RP-HPLC. Concentrated in vacuo to afford title compound **4** (40.0 mg). MS, electrospray, m/z = 603.4 $[\text{M}+\text{H}]$, RT 0.78 min.

The following compounds from Table 1 are prepared according to the procedure described in Example 10, using the appropriate amine, other appropriate starting materials and purification conditions:


Compound **26**: MS, electrospray, $m/z = 575.3$ [M+H], RT 0.73 min;

Compound **29**: MS, electrospray, $m/z = 589.3$ [M+H], RT 0.77 min;

Compound **82**: MS, electrospray, $m/z = 561.3$ [M+H], RT 0.82 min;

Compound **96**: MS, electrospray, $m/z = 589.4$ [M+H], RT 0.96 min.

Example 11: Preparation of intermediate 2,2-difluoro-cyclopropanecarbaldehyde (11-46)




EDCI (1.4g, 7.1 mmol) is added to a mixture of N,O-dimethylamine hydrochloride (600 mg, 6.2 mmol) and 2,2-difluorocyclopropane carboxylic acid, **11-45**, (580 mg, 4.8 mmol) in dichloromethane (15 mL) at room temperature. N,N-Diisopropylethylamine (3.3 mL, 19.0 mmol) is added and the mixture is stirred for 3 h. A solution of 1N HCl is added, followed by vigorous stirring for 10 min. The organic phase is separated using a hydrophobic frit and applied directly to a 10 g SiO₂ samplelet. The crude material is purified on a 50 g HP-Sil SNAP cartridge (Biotage) eluting with 9:1 dichloromethane/MeOH. The solvent is removed from product containing fractions via short-path distillation at atmospheric pressure (bath temp of 70 °C) to afford **11-46** (605 mg).

A solution of **11-46**, (605 mg, 3.66 mmol) in dichloromethane at -78 °C is treated dropwise with DIBAL-H (4.2 mL, 1.0 M in dichloromethane) and then is stirred 2.5 h at -78 °C. The reaction is quenched by addition of saturated aqueous Rochelle salt solution. An equal volume of water is added and the mixture is warmed to room temperature. The mixture is vigorously stirred for 3


h, followed by separation of the organic phase with a hydrophobic frit. The dichloromethane is removed by short path distillation at atmospheric pressure (bath temp = 62 °C) to afford **11-47** (389 mg).

Example 12: Preparation of 1-(6-{2-[2-(2,2-difluoro-cyclopropylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-3-methyl-phenyl}-pyridin-2-yl)-5-methoxy-1H-pyrazole-4-carboxylic acid (72**)**




Amine **12-48** (90.0 mg, 0.18 mmol) is combined with 4Å molecular sieves (20 mg), 2,2-difluoro-cyclopropanecarboxaldehyde, **11-47**, (60.0 mg, 0.54 mmol), AcOH (20 µL), and Na(CN)BH₃ (34.0 mg, 0.54 mmol) in MeOH (4.0 mL). The mixture is stirred at room temperature for 30 min, and then heated to 50 °C for 12 h. The mixture is diluted with THF (1.0 mL) and water (1.0 mL). To this is added LiOH (33.00 mg, 1.43 mmol) and the reaction is heated to 50 °C for 2 h. It is then concentrated under N₂, triturated with 1:1 MeOH/DMSO, filtered through a 0.45 micron syringe filter, and the filtrate is purified by gradient elution (10-100% MeOH/water + 0.1% HCO₂H) on a Gilson RP-HPLC. Concentrated in vacuo to afford title compound **72** (7.0 mg). MS, electrospray, m/z = 561.3 [M+H], Method A2, RT 1.59 min.

Example 13: Preparation of 5-methoxy-1-(6-{3-methyl-2-[2-(2,2,2-trifluoro-ethyl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-phenyl}-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (11**)**




2,2,2-Trifluoroethyl triflate, **13-49**, (36.0 μL , 0.23 mmol) is added to a mixture of intermediate **12-48** (106.0 mg, 0.21 mmol) and N,N-diisopropylethylamine (190 μL , 1.10 mmol) in MeCN (5.0 mL). The mixture is heated to 45 $^{\circ}\text{C}$ for 4 h and then concentrated in vacuo. The remaining residue is redissolved in 5 mL of THF/MeOH/water (2:2:1) and treated with LiOH (25.0 mg, 1.10 mmol). The mixture is then heated to 50 $^{\circ}\text{C}$ for 2 h prior to removal of the solvents in vacuo. The remaining crude residue is purified by gradient elution on a 30 g KP-C18 SNAP cartridge (Biotage) using a gradient of 5-95% MeCN/water + 0.1% TFA to afford title compound **11** (103 mg). MS, electrospray, m/z = 553.2 $[\text{M}+\text{H}]$, Method A2, RT 1.13 min.

Example 14: Preparation of intermediate 1-methyl-5-oxo-pyrrolidine-3-carbaldehyde (14-51)




Alcohol **14-50** (0.20 g, 1.55 mmol) is combined with polystyrene-bound IBX resin (5.81 g) in dichloromethane (20.0 mL) in a sealed 40 mL vial and is rotated end over end for 20 h. The reaction mixture is filtered away from the resin, and the resin is rinsed several times [first with dichloromethane (10 mL), then with a 1:1 dichloromethane/MeOH (20 mL), again with 1:1 dichloromethane /MeOH (20 mL), and finally with dichloromethane (10 mL)]. The combined filtrates are concentrated under a stream of N_2 to yield a mixture of **14-50** and desired product **14-51**.

Example 15: Preparation of 5-ethoxy-1-(6-{3-methyl-2-[2-(1-methyl-5-oxo-pyrrolidin-3-ylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-phenyl}-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (97**)**



Amino acid **60** (40.0 mg, 0.07 mmol) is combined with 4Å molecular sieves (20 mg), **14-51** (51.0 mg, 0.200 mmol), AcOH (15.0 μ L), and Na(CN)BH₃ (13.2 mg, 0.20 mmol) in MeOH (2.0 mL). The mixture is stirred at room temperature for 30 min and then heated to 50 °C for 12 h. The crude is purified by reverse phase column chromatography on C18 (using a solvent gradient of 5-95% MeCN/H₂O + 0.1% TFA) to afford title compound **97** (27.0 mg). MS, electrospray, m/z = 596.4 [M+H], RT 0.80 min.

Example 16: Preparation of 5-ethoxy-1-(6-{3-methyl-2-[2-(tetrahydro-furan-2-ylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-phenyl}-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (101**)**



To a mixture of amine **8-42** (100.0 mg, 0.20 mmol) and N,N-diisopropylethylamine (0.10 mL, 0.59 mmol) in DMF (1.00 mL) is added 2-bromomethyltetrahydrofuran (8.0 mg, 0.05 mmol) in DMF (0.06 mL). The mixture is irradiated at 100 °C for 10 min and cooled to room temperature. Excess bromide (76.0 mg) is added and the reaction is irradiated multiple times and then stirred at room temperature for 24 h. The reaction mixture is filtered and the filtrate is purified by HPLC (using a solvent gradient of 10-95% MeCN/H₂O + 0.1% Formic Acid) to provide **16-52** (6.0 mg).


16-52 (6.0 mg) is diluted with THF (1.0 mL), water (1.0 mL) and MeOH (1.0 mL). To this is added LiOH (5.0 mg) and the reaction is heated to 50 °C for 2 h. The reaction mixture is cooled to room temperature, acidified with 4 N HCl in 1,4-dioxane, and filtered. The filtrate is purified by HPLC (using a solvent gradient of 10-95% MeCN/H₂O + 0.1% Formic Acid) to provide title compound **101** (1.0 mg). MS, electrospray, m/z = 569.4 [M+H], RT 0.88 min.

The following compound from Table 1 is prepared according to the procedure described in Example **16**, using the appropriate starting materials and purification conditions:

Compound **138**: MS, electrospray, m/z = 639.4 [M+H], RT 1.16 min;

Compound **160**: MS, electrospray, m/z = 563.3 [M+H], RT 0.96 min.

Example 17: Preparation of 1-(6-{2-[2-(2-hydroxy-2-methyl-propyl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-3-methyl-phenyl}-pyridin-2-yl)-5-methoxy-1H-pyrazole-4-carboxylic acid (33**)**




Intermediate **12-48** (90.0 mg, 0.18 mmol) is dissolved in MeCN (5.0 mL) to which is added Cs_2CO_3 (117.9 mg, 0.36 mmol) and chloride **17-53** (29.5 mg, 0.27 mmol). The mixture is heated to 50 °C for 10 h. The reaction was cooled, extracted with EtOAc, washed with brine, dried over MgSO_4 , and concentrated. The resulting material is purified by gradient elution on a 30 g KP-C18 SNAP cartridge (Biotage) using a gradient of 15-65% MeCN/water + 0.1% TFA to afford the intermediate ester. The ester is dissolved in 5 mL of THF/MeOH/water (2:2:1) and treated with LiOH (25.0 mg, 1.10 mmol). The mixture is then heated to 50 °C for 2 h prior to removal of the solvents in vacuo. The remaining crude residue is purified by gradient elution on a 30 g KP-C18 SNAP cartridge (Biotage) using a gradient of 15-65% MeCN/water + 0.1% TFA to afford title compound **33** (103.0 mg). MS, electrospray, $m/z = 543.2$ $[\text{M}+\text{H}]$, RT 0.68 min.

The following compound from Table 1 is prepared according to the procedure described in Example 17, using the appropriate starting materials and purification conditions:

Compound **74**: MS, electrospray, $m/z = 577.3$ $[\text{M}+\text{H}]$, RT 0.67 min;

Compound **168**: MS, electrospray, $m/z = 587.3$ $[\text{M}+\text{H}]$, RT 0.70 min.

Example 18: Preparation of 6-Bromomethyl-8-trifluoromethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (18-10)



Commercial acid **18.1** (5.0g, 22.7 mmol) is dissolved in THF (30 mL) at rt. A 1M solution of borane in THF (34.0 mL, 34.0 mmol) is added dropwise via syringe. The mixture is then heated to 55 °C o/n before cooling to rt and quenching with water (5 mL). After stirring for 5 min, 12 mL of 2N HCl is added and the mixture is stirred 1h. dichloromethane (50 mL) and water (50 mL) are then added, and the resulting phases are separated with a hydrophobic frit. The organic layer is further dried over Na_2SO_4 , then refiltered. Concentrated in vacuo to affords an oil that is purified by gradient elution (5-100% EtOAc/heptane) on a 100g KP-Sil SNAP cartridge (Biotage). Concentration of the product fractions delivers intermediate **18.2** (3.2 g)

Thionyl chloride (SOCl_2) (2.3 mL, 31.5 mmol) is added to a solution of alcohol **18.2** (3.2 g, 15.5 mmol) in dichloromethane (20 mL) under N_2 at -10°C . After 5 min, the cooling bath is removed and the mixture is heated to reflux for 6h. The resulting solution is cooled to rt and concentrated in vacuo. The remaining residue is then azeotroped with PhMe (2 x 10 mL) and then dissolved in DMF (20 mL). Solid NaCN (840 mg, 17.1 mmol) is added and the mixture is heated to 45°C o/n. Upon cooling to rt, the mixture is diluted with water (25 mL), brine (25 mL), and EtOAc (50 mL). The layers are separated, and the organics are dried over Na_2SO_4 , filtered, and concentrated in vacuo. Crude product is purified by gradient elution (5-100% EtOAc/heptane) on a 100g KP-Sil SNAP cartridge (Biotage). Product fractions concentrated in vacuo to afford **18-3** (3.0 g).

A 1M solution of borane in THF (35 mL, 35 mmol) is added dropwise via syringe to a solution of **18-3** (3.0 g, 13.9 mmol) in THF (25 mL) at rt. The mixture is then heated to 55°C o/n before cooling to rt, and quenching with water (5 mL). After 5 min of stirring, conc. HCl (8 mL) is added and stirring is continued for 1h. The mixture is then diluted with water (20 mL), and treated with solid NaOH until alkaline. dichloromethane (50 mL) and brine (25 mL) are added, then the layers are separated with a hydrophobic frit. The crude amine is purified by gradient elution (5-95% MeCN/water + 0.1% TFA) on a 120g KP-C18 SNAP cartridge (Biotage). Concentration of the fractions in vacuo affords an intermediate TFA salt (2.93 g) that is dissolved in HCO_2H (30 mL) and treated with 37% aq. HCHO (0.66 mL, 8.8 mmol). The mixture is stirred at 50°C o/n, then concentrated in vacuo to afford a crude solid that is immediately dissolved in 48% aq. HBr (25 mL). This solution is heated to 100°C o/n, then concentrated in vacuo. The crude material is azeotroped with PhMe (3 x 15 mL), then slurried in dichloromethane (50 mL) and DMF (10 mL). Et_3N (1.9 mL, 0.82 mmol) and a few crystals of 4-DMAP are added. Boc_2O (2.0 g, 9.1 mmol) is added in one portion, and the mixture is stirred at rt o/n. Saturated NH_4Cl solution (50 mL) is added and the layers are separated with a hydrophobic frit. The organic is concentrated in vacuo to afford a crude residue that is purified by gradient elution (5-100% EtOAc/heptane) on a 100g KP-Sil SNAP cartridge (Biotage). Concentration of the product fractions afforded **18-5** (540 mg).

Tf₂O (0.27 mL, 1.6 mmol) is added via syringe to a mixture of **18-5** (540 mg, 1.46 mmol), Et₃N (0.31 mL, 2.2 mmol) and 4-DMAP (18 mg, 0.15 mmol) in dichloromethane (25 mL) cooled to 0 °C. The mixture is stirred with warming to rt o/n, and then quenched with sat. NaHCO₃ (30 mL). The resulting layers are separated with a hydrophobic frit, and the organics are concentrated under N₂. The crude residue is purified by gradient elution (5-30% EtOAc/heptane) on a 50g HP-Sil SNAP cartridge (Biotage). Concentration of the product fractions in vacuo affords **18-6** (460 mg).

Triflate **18-6** (460 mg, 1.02 mmol) is combined with vinylboronic acid-pyridine complex (250 mg, 1.04 mmol) and Pd(PPh₃)₄ (60 mg, 0.05 mmol) in a mixture of DME (9 mL) and 2M aq. Na₂CO₃ solution. The mixture is irradiated in Biotage microwave at 120 °C for 40 min. Upon cooling, then mixture is concentrated under N₂, and the crude solids are triturated with dichloromethane. The dichloromethane filtrate is then purified by gradient elution (5-80% EtOAc/heptane) using a 50g HP-Sil SNAP cartridge (Biotage). Product fractions concentrated in vacuo to afford **18-7** (275 mg).




Styrene **18-7** (275 mg, 0.84 mmol) and NaIO₄ (630 mg, 2.95 mmol) are combined in a mixture of THF (12 mL) and water (3 mL) at rt. OsO₄ (0.13 mL, 0.017 mmol, 4 wt% in H₂O) is added via syringe and the resulting slurry is stirred vigorously o/n at rt. The slurry is then filtered through a frit, and concentrated in vacuo. The remaining residue is dissolved in dichloromethane (20 mL), and washed with saturate aq. thiosulfate solution (25 mL). The layers are then separated with a hydrophobic frit, and the organic concentrated in vacuo. Purification of the crude residue by gradient elution (5-60% EtOAc/heptane) on a 25g HP-Sil SNAP cartridge (Biotage) affords **18-8** (228 mg).

Aldehyde **18-8** (225 mg, 0.683 mmol) is dissolved in THF (5 mL) and then MeOH (5 mL). Solid NaBH₄ (40 mg, 1.1 mmol) is added, and the mixture is stirred at rt for 20 min. Aqueous sat. NH₄Cl (ca 50 mL) is added and the mixture is stirred for 15 min. EtOAc (100 mL) and brine (100 mL) are added, then the layers are separated. The organic is dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude product is purified by gradient elution (5-100%

EtOAc/heptane) on a 50g HP-Sil SNAP cartridge (Biotage). Concentration of the product fractions in vacuo affords **18-9** (225 mg).

Solid Ph_3PBr_2 (450 mg, 1.02 mmol) is added to a mixture of **18-9** (225 mg, 0.68 mmol) and DIPEA (0.21 mL, 1.2 mmol) in dichloromethane at 0 °C. The mixture is stirred for 1 hour, and then concentrated in vacuo. The crude bromide is purified by gradient elution (5-40% EtOAc/heptanes) on a 25g HP-Sil SNAP cartridge (Biotage) to afford **18-10** (248 mg).

Similarly, the following bromides were prepared from the appropriate starting materials as described in Example 18:

18-11	
18-12	
18-13	

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, **2-8**, bromide, **18-10**, and other appropriate starting materials and purification conditions:

Compound **158**: MS, electrospray, $m/z = 623.3$ $[\text{M}+\text{H}]$, RT 1.34 min (Method B2).

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, **3-15**, bromide, **18-10**, and other appropriate starting materials and purification conditions:

Compound **157**: MS, electrospray, $m/z = 637.3$ [M+H], RT 0.67 min (Method B2).

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, **2-8**, bromide, **18-11**, and other appropriate starting materials and purification conditions:

Compound **201**: MS, electrospray, $m/z = 573.3$ [M+H], RT 1.14 min (Method B2);

Compound **202**: MS, electrospray, $m/z = 589.3$ [M+H], RT 1.14 min (Method B2);

Compound **229**: MS, electrospray, $m/z = 587.3$ [M+H], RT 1.46 min (Method B2);

Resolution: LUX 5u Cellulose 3 Prep 14% (1:1:1 MeOH:EtOH:iPA):CO₂, 40°C, 110 bar, 80ml/min

Compound **230**: MS, electrospray, $m/z = 559.3$ [M+H], RT 1.46 min (Method B2).

Resolution: LUX 5u Cellulose 3 Prep 14% (1:1:1 MeOH:EtOH:iPA):CO₂, 40°C, 110 bar, 80ml/min

Compound **253**: MS, electrospray, $m/z = 559.4$ [M+H], RT 1.20 min (Method A2) (Med Polar Long).

Compound **254**: MS, electrospray, $m/z = 559.3$ [M+H], RT 1.20 min (Method A2) (Med Polar Long).

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, **2-8**, bromide, **18-12**, and other appropriate starting materials and purification conditions:

Compound **177**: MS, electrospray, $m/z = 545.2$ [M+H], RT 0.68 min (Method B1);

Compound **187**: MS, electrospray, $m/z = 575.3$ [M+H], RT 1.13 min (Method B2);

Compound **231**: MS, electrospray, $m/z = 589.3$ [M+H], RT 1.26 min (Method B2);

Resolution: LUX 5u Cellulose 4 Prep 20% 1:1:1 MeOH:EtOH:iPA (0.1% Et₂NH):CO₂ @ 75 ml/min., 130 bar, 40°C

Compound **234**: MS, electrospray, m/z = 589.3 [M+H], RT 1.26 min (Method B2);

Resolution: LUX 5u Cellulose 4 Prep 20% 1:1:1 MeOH:EtOH:iPA (0.1% Et₂NH):CO₂ @ 75 ml/min., 130 bar, 40°C

Compound **251**: MS, electrospray, m/z = 559.4 [M+H], RT 1.18 min (Method A2) (Med Polar Long).

Resolution: ChiralPak AD-H Prep 45% 3:1 hexane:EtOH (1% iPrNH₂):CO₂ @ 80 ml/min., 100 bar, 25°C

Compound **252**: MS, electrospray, m/z = 559.3 [M+H], RT 1.18 min (Method A2) (Med Polar Long).

Resolution: ChiralPak AD-H Prep 45% 3:1 hexane:EtOH (1% iPrNH₂):CO₂ @ 80 ml/min., 100 bar, 25°C

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **2-8**, bromide, **18-13**, and other appropriate starting materials and purification conditions:

Compound **166**: MS, electrospray, m/z = 623.3 [M+H], RT 1.30 min (Method B2).


The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-15**, bromide, **18-12**, and other appropriate starting materials and purification conditions:

Compound **159**: MS, electrospray, m/z = 587.3 [M+H], RT 0.61 min (Method B1).

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-15**, bromide, **18-13**, and other appropriate starting materials and purification conditions:

Compound **165**: MS, electrospray, m/z = 637.3 [M+H], RT 1.42 min (Method B2).

Example 19: Preparation of intermediate 7-Hydroxymethyl-6-methyl-1,2,4,5-tetrahydro-benzo[d]azepine-3-carboxylic acid tert-butyl ester (19-14)



A solution of compound **19-1** (100g, 0.465 mol) in THF (800.000 ml) is added to a mixture of LAH (166g, 1.395 mol) in anhydrous THF (200 ml) at 0 °C. The mixture is stirred at room temperature for 0.5 h, then is refluxed for 1 h. TLC showed the reaction is completed. A saturated aqueous NH₄Cl (200 ml) is slowly added to the mixture. Then EtOAc and Na₂SO₄ are added. The mixture is stirred for 1 h, and then is filtered and washed by PE to afford compound **19-2**.

To a solution of compound **19-2** (360.000 g, 2.365 mol) in dichloromethane (3000.000 ml) is added SOCl_2 (562.980 g, 4.731 mol) at $-10\text{ }^\circ\text{C}$. Then the reaction mixture is refluxed for 4 h. The mixture is concentrated to afford crude compound **19-3** which is used directly in the next step.

A mixture of compound **19-3** (334.000 g, 1.957 mol) and NaCN (168.096 g, 2.290 mol) in DMF (1000.000 ml) is stirred at room temperature overnight. The mixture is extracted with EtOAc and H_2O . The organic layer is dried and concentrated, and purified by chromatography on silica gel (PE: EA = 50:1) to give compound **19-4** as a yellow oil.

A mixture of compound **19-4** (1608.000 g, 9.975 mol), KOH (1117.221 g, 19.950 mol) in EtOH (15000.000 ml) is heated to reflux for 5 h. TLC showed the reaction is completed. The solvent is removed under reduced pressure. The residue is adjusted to pH = 1. The mixture is filtered and the filter cake is dried to yield compound **19-5**.

Compound **19-5** (737.000 g, 4.090 mol) is added to a stirred solution of $(\text{COCl})_2$ (8.180 mol) and DMF (70.000 ml) in dichloromethane (7370.000 ml) under N_2 atmosphere, followed by stirring for 2 h. TLC showed the reaction is completed. Then the mixture is evaporated. The residue was added to a stirred solution of 2,2-dimethoxyethyl-1-amine (429.996 g, 4.090 mol) and Et_3N (454.388 g, 4.499 mol) in dichloromethane (1000 ml) at room temperature for 2 h. TLC showed the reaction is completed. The mixture is evaporated and the residue is purified by column to give compound **19-6**.

A solution of compound **19-6** (1053 g, 3.939 mol) in AcOH (2 L) and HCl (2 L) is stirred at room temperature for 16 h. TLC showed the reaction is completed. The mixture is evaporated. The residue is crystallized, washed with H_2O and EtOH, and then the solid is filtered and dried to give compound **19-7**.

A mixture of Pd/C (4 g) and compound **19-7** (40.000 g, 0.197 mol) in AcOH (2 L) is stirred at room temperature under H_2 for 16 h. LCMS showed the reaction is completed. The mixture is

filtered, evaporated, and the residue is crystallized with EtOH. The solid is filtered and dried to give compound **19-8**.

To a stirred solution of compound **19-8** (130.000 g, 0.633 mol) in THF (1300.000 ml) is added BMS₂ (127.000 ml, 1.267 mol) slowly under N₂ atmosphere, meanwhile the temperature is maintained below -5 °C, followed by stirring for 16 h. LCMS showed the reaction is completed. The reaction is quenched with conc. HCl and then the mixture is refluxed for 2 h. The solvent is evaporated and the residue is separated with dichloromethane and H₂O. The aqueous phase is adjusted to pH = 9 and the solid is filtered and dried to give compound **19-9**.

A solution of compound **19-9** (220.000 g, 1.150 mol) in 48% HBr aqueous (1800.000 ml) is stirred at 110 °C for 4 h under N₂ atmosphere. LCMS showed the reaction is completed. The mixture is evaporated to give crude compound **19-10**.


A mixture of compound **19-10** (267.000 g, 1.506 mol), Boc₂O (492.595 g, 2.260 mol) and TEA (380.368 g, 3.766 mol) in dichloromethane (2670.000 ml) is stirred at room temperature for 2 h. The reaction is monitored by TLC. When compound **19-10** is consumed, the reaction mixture is concentrated under reduce pressure and the residue was purified by column chromatography to give compound **19-11**.

A mixture of compound **19-11** (267.000 g, 0.963 mol) and Tf₂O (271.468 g, 0.963 mol) in (2670.000 ml) is stirred at room temperature for 2 h under N₂ atmosphere. TLC showed the reaction is completed. The reaction mixture is concentrated under reduce pressure and the residue is purified by column to give compound **19-12**.

A mixture of compound **19-12** (20.000 g, 0.049 mol), dppp (2.000 g), Pd(OAc)₂ (2.000 g) and TEA (9.868 g, 0.098 mol) in EtOH (400.000 ml) is stirred at 80 °C for 12 h under CO atmosphere. The reaction is monitored by TLC. When the reaction is completed, the reaction mixture is concentrated under reduce pressure and the residue is purified by column chromatography to give compound **19-13**.

To a stirred solution of compound **19-13** (22.000 g, 0.066 mol) in THF (300.000 ml) is slowly added LAH (2.507 g, 0.066 mol), meanwhile the temperature is maintained below -40 °C. After addition is completed, the mixture is stirred at room temperature for 2 h. TLC showed the reaction is completed and the reaction is quenched with H₂O. The solvent is removed under reduced pressure and the residue is separated with dichloromethane and H₂O, the organic phase is dried over anhydrous Na₂SO₄, and evaporated. The residue was purified by column to give compound **19-14**.

Bromination of the alcohol is performed similarly to that of **Example 4** to yield intermediate 7-Bromomethyl-6-methyl-1,2,4,5-tetrahydro-benzo[d]azepine-3-carboxylic acid tert-butyl ester **19-15**.



The following compound from Table 1 is prepared according to the procedure described in **Example 7a**, using phenol, **2-8**, bromide, **19-15**, and other appropriate starting materials and purification conditions:

Compound **176**: MS, electrospray, $m/z = 555.3$ [M+H], RT 1.19 min (Method B2);

Compound **184**: MS, electrospray, $m/z = 583.3$ [M+H], RT 1.24 min (Method B2);

Compound **206**: MS, electrospray, $m/z = 569.3$ [M+H], RT 1.26 min (Method B2);

Resolution: LUX 5u Cellulose 4 Prep, 20% MeOH:EtOH:IPA (1:1:1) (0.1% Et₂NH) in CO₂ at 705ml/min, 130 Bar, 40°C.

Compound **207**: MS, electrospray, $m/z = 569.3$ [M+H], RT 1.26 min (Method B2);

Resolution: LUX 5u Cellulose 4 Prep, 20% MeOH:EtOH:IPA (1:1:1) (0.1% Et₂NH) in CO₂ at 705ml/min, 130 Bar, 40°C.

Compound **222**: MS, electrospray, $m/z = 583.3$ [M+H], RT 1.40 min (Method B2);

Resolution: LUX 5u Cellulose 1 Prep, 12% MeOH:IPA (1% Et₂NH) in CO₂ at 70ml/min, 105 Bar, 40°C.

Compound **223**: MS, electrospray, $m/z = 583.4$ [M+H], RT 1.42 min (Method B2);

Resolution: LUX 5u Cellulose 1 Prep, 12% MeOH:IPA (1% Et₂NH) in CO₂ at 70ml/min, 105 Bar, 40°C.

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, 3-15, bromide, 19-15, and other appropriate starting materials and purification conditions:

Compound **162**: MS, electrospray, m/z = 597.3 [M+H], RT 1.34 min (Method B2);

Compound **175**: MS, electrospray, m/z = 569.3 [M+H], RT 1.31 min (Method B2);

Compound **190**: MS, electrospray, m/z = 597.2 [M+H], RT 0.63 min (Method B1);

Compound **196**: MS, electrospray, m/z = 585.3 [M+H], RT 0.67 min (Method B1);

Compound **203**: MS, electrospray, m/z = 599.3 [M+H], RT 0.67 min (Method B1)

Resolution: Chirapak AD-H, 20x250mm; 20%EtOH:Heptane@ 8 mL/min., ambient temp.

Compound **204**: MS, electrospray, m/z = 599.3 [M+H], RT 0.67 min (Method B1)

Resolution: Chirapak AD-H, 20x250mm; 20%EtOH:Heptane@ 8 mL/min., ambient temp.

Compound **211**: MS, electrospray, m/z = 613.3 [M+H], RT 1.43 min (Method B2);

Resolution : LUX 5u Cellulose 1 Prep 20% iPA+Et₂NH:Heptane @ 9ml/min

Compound **212**: MS, electrospray, m/z = 613.3 [M+H], RT 1.43 min (Method B2);

Resolution : LUX 5u Cellulose 1 Prep 20% iPA+Et₂NH:Heptane @ 9ml/min

Compound **214**: MS, electrospray, m/z = 611.3 [M+H], RT 1.61 min (Method B2);

Resolution: LUX 5u Cellulose 1 Prep 30% iPA:CO₂, 110bar, 75ml/min, 40°C

Compound **215**: MS, electrospray, m/z = 611.3 [M+H], RT 1.61 min (Method B2);

Resolution: LUX 5u Cellulose 1 Prep 30% iPA:CO₂, 110bar, 75ml/min, 40°C

Compound **225**: MS, electrospray, m/z = 583.3 [M+H], RT 1.41 min (Method B2);

Resolution: LUX 5u Cellulose 4 Prep 20% 1:1:1 MeOH:EtOH:iPA (0.1% Et₂NH) : CO₂ @ 75 g/min., 110 bar, 40°C

Compound **226**: MS, electrospray, m/z = 583.3 [M+H], RT 1.44 min (Method B2);

Resolution: ESI Industries CC4 Prep 55% 1:1 hexane:MeOH (3% iPrOH, 0.1% iPrNH₂):CO₂ @ 80 ml/min., 100 bar, 25°C

Compound **227**: MS, electrospray, m/z = 583.3 [M+H], RT 1.41 min (Method B2);

Resolution: LUX 5u Cellulose 4 Prep

20% 1:1:1 MeOH:EtOH:iPA (0.1% Et₃NH) : CO₂ @ 75 g/min., 110 bar, 40°C

Compound **235**: MS, electrospray, m/z = 583.3 [M+H], RT 1.41 min (Method B2);

Resolution: LUX 5u Cellulose 4 Prep

20% 1:1:1 MeOH:EtOH:iPA (0.1% Et₃NH) : CO₂ @ 75 g/min., 110 bar, 40°C

Compound **228**: MS, electrospray, m/z = 583.3 [M+H], RT 1.44 min (Method B2);

Resolution: ESI Industries CC4 Prep 55% 1:1 hexane:MeOH (3% iPrOH, 0.1% iPrNH₂):CO₂ @ 80 ml/min., 100 bar, 25°C

Compound **232**: MS, electrospray, m/z = 597.3 [M+H], RT 1.54 min (Method A2);

Resolution: LUX 5u Cellulose 1 Prep 7% EtOH:Heptane @ 10ml/min


Compound **233**: MS, electrospray, m/z = 597.3 [M+H], RT 1.50 min (Method A2);

Resolution: LUX 5u Cellulose 4 Prep 20% EtOH:CO₂, 80ml/min, 110bar, 40°C

Compound **235**: MS, electrospray, m/z = 597.3 [M+H], RT 1.50 min (Method A2);

Resolution: LUX 5u Cellulose 4 Prep 20% EtOH:CO₂, 80ml/min, 110bar, 40°C

Example 20. Preparation of intermediate 5-Bromomethyl-4,7-dimethyl-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester (20-4).



To a 100 mL round bottom flask is added amine **20-1** (0.500 g, 4.13 mmol) which is dissolved in dichloromethane (15.0 mL). The reaction mixture is cooled to 0 °C and triethylamine (1.15 mL, 8.25 mmol) and BOC₂O (1.35 g, 6.19 mmol) are added. The reaction is warmed to room temperature and stirred overnight. The reaction is extracted with dichloromethane, washed with water and brine, dried over MgSO₄ and concentrated. The resulting residue is purified by silica gel chromatography using a gradient of 12-100% EtOAc in heptanes. The desired fractions are collected and concentrated yielding an oil (0.556 g).

Propargyl alcohol (0.579 mL, 9.94 mmol) is added dropwise at 0 °C to a solution of diacetylene **20-2** (0.550 g, 2.49 mmol) in anhydrous ethanol (15.0 mL). Wilkinson's catalyst (0.229 g, 0.249

mmol) is added and the mixture is stirred for 16 h at room temperature. The crude reaction is concentrated and subjected to silica gel chromatography using a gradient of 10-80% EtOAc in heptanes. The desired fractions are collected and concentrated yielding an off-white solid (0.125 g).


To a solution of alcohol **20-3** (125 mg, 0.451 mmol) and N,N-diisopropylethylamine (0.118 mL, 0.676 mmol) in dichloromethane (5.0 mL) is added triphenylphosphine dibromide (297 mg, 0.676 mmol) at 0 °C. The reaction is stirred for 2 h and concentrated in vacuo. The resulting residue is purified by silica gel chromatography using a gradient of 7-60% EtOAc in heptanes to yield the desired product **20-4** (35.0 mg) as a white solid.

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, **2-8**, bromide, **20-4**, and other appropriate starting materials and purification conditions:

Compound **145**: MS, electrospray, $m/z = 569.3$ [M+H], RT 0.75 min;

Compound **246**: MS, electrospray, $m/z = 585.0$ [M+H], RT 1.40 min (Method B2);

Example 21. Preparation of intermediate 6-Bromomethyl-5,8-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (21-8).



Ketone **21-1** (14.00 g, 70.27 mmol) and pyrrolidine (8.71 mL, 106.0 mmol) are dissolved in toluene (60 mL) and the mixture is refluxed under Dean Stark conditions for 24 h. The reaction is then concentrated in vacuo. The resulting residue is dissolved in toluene (60 mL) and treated with 4-hexen-3-one (8.32 mL, 70.27 mmol) and hydroquinone (0.080 g, 0.727 mmol). The solution is heated to reflux for 24 h and then diluted with EtOAc and washed with 1N HCl. The combined organics are dried and concentrated in vacuo to afford a viscous oil. The material is purified by silica gel chromatography using a gradient of 20-100% EtOAc in heptanes to afford a yellow solid (11.74 g).

A 1.0 M LiHMDS solution (42.95 mL) is added dropwise to a solution of intermediate **21-2** (10.00 g, 35.79 mmol) in THF (50.0 mL) at -78 °C. This mixture is stirred at -78 °C for an additional 30 min. TMS-Cl (5.45 mL, 42.95 mmol) is added dropwise and stirred at -78 °C for 2 h. The reaction is warmed to room temperature and diluted with diethyl ether (200 mL). This mixture is added to a saturated Na_2CO_3 solution and the phases are separated. The combined organics are dried and concentrated in vacuo. The residue is dissolved in ACN (50.0 mL) and $\text{Pd}(\text{OAc})_2$ (8.04 g, 35.79 mmol) is added. The resulting mixture is cooled in a water bath to maintain reaction temp below 35 °C and stirred overnight. The reaction is filtered through celite and the filtrate is concentrated in vacuo. The residue is taken up in 200 mL EtOAc then treated

with 1.0 M TBAF solution (50.0 mL). This mixture is stirred for 30 min and then washed with 1N HCl and 10% sodium thiosulfate solution. The organics are dried and concentrated. The material is purified by silica gel chromatography using a gradient of 20-80% EtOAc in heptanes to afford an off-white solid (6.11 g).

To a solution of starting material **21-3** (1.50 g, 5.41 mmol) in dichloromethane (25.0 mL) at room temperature is added pyridine (0.871 mL, 10.82 mmol). The solution is cooled to -30 °C and Tf₂O (1.00 mL, 5.95 mmol) is added dropwise. The reaction is stirred at -30 °C for 1 h and then is warmed to room temperature. It is concentrated in vacuo and the residue is diluted with EtOAc, washed with 1 N HCl, saturated NaHCO₃, brine, dried over MgSO₄, and concentrated. The resulting material is purified by silica gel chromatography using a gradient of 12-100% EtOAc in heptanes to yield a white solid (1.61 g).

Triflate **21-4** (1.00 g, 2.44 mmol) is combined with the boronate (0.647 g, 2.69 mmol) and Pd(PPh₃)₄ (0.144 g, 0.124 mmol) in a mix of DME (15.0 mL) and 2.0 M Na₂CO₃ (1.27 mL). The reaction is irradiated in MW at 120 °C for 40 min. It is concentrated under N₂ and is purified by silica gel chromatography using a gradient of 12-100% EtOAc in heptanes. The desired fractions are concentrated to afford a white solid (0.662 g).


Substrate **21-5** (1.029 g, 3.58 mmol), NaIO₄ (2.34 g, 10.94 mmol), 2.5 wt % OsO₄ in *t*-BuOH (1.0 mL), THF (12.4 mL) and H₂O (2.4 mL) are combined at room temperature, then stirred overnight in the dark. The reaction mixture is diluted with water and dichloromethane. The layers are separated with a hydrophobic frit. The organics are dried over Na₂SO₄, filtered, and concentrated. The residue is purified by silica gel chromatography using a gradient of 12-100% EtOAc in heptanes to yield an amber oil (0.786 g).

Aldehyde **21-6** (0.785 g, 2.71 mmol) is dissolved in THF (5.0 mL) and MeOH (5.0 mL). The mixture is cooled to 0 °C and NaBH₄ (0.156 g, 4.07 mmol) is added. The reaction is stirred at room temperature for 30 min. The reaction is quenched with aq. NH₄Cl and is stirred for 10 min. It is extracted with EtOAc, washed with NH₄Cl, brine, dried over MgSO₄, and concentrated. The resulting material is purified by silica gel chromatography using a gradient of 12-100% EtOAc in

heptanes. The desired fractions are collected to yield the desired product **21-7** (0.626 g) as a white solid.

To a solution of alcohol **21-7** (0.300 g, 1.030 mmol) and N,N-diisopropylethylamine (0.269 mL, 1.54 mmol) in dichloromethane (10.0 mL) is added triphenylphosphine dibromide (0.679 g, 1.54 mmol) at 0 °C. The reaction is stirred for 2 h and concentrated in vacuo. The resulting residue is purified by silica gel chromatography using a gradient of 7-60% EtOAc in heptanes to yield the desired product **21-8** (0.338 g) as a white solid.

Similarly, the following bromides were prepared from the appropriate starting materials as described in Example **21**:



The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **2-8**, bromide, **21-8**, and other appropriate starting materials and purification conditions:

Compound **120**: MS, electrospray, m/z = 583.5 [M+H], RT 0.74 min;

Compound **178**: MS, electrospray, m/z = 555.3 [M+H], RT 0.64 min (Method B1).


The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-15**, bromide, **21-8**, and other appropriate starting materials and purification conditions:

Compound **132**: MS, electrospray, m/z = 597.5 [M+H], RT 0.83 min.

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, **3-15**, bromide, **21-9**, and other appropriate starting materials and purification conditions:

Compound **154**: MS, electrospray, $m/z = 597.7$ [M+H], RT 0.81 min.

Example 22. Preparation of intermediates 5-Bromomethyl-4-methyl-1,3-dihydro-isindole-2-carboxylic acid tert-butyl ester (22-5) and 6-Bromomethyl-4-methyl-1,3-dihydro-isindole-2-carboxylic acid tert-butyl ester (22-6)



To a stirred solution of Boc-amine **22-1** (2.00 g, 12.89 mmol) in THF (30.0 mL) and tetrabutylammonium iodide (0.476 g, 1.29 mmol) is added 0.5 M KHMDS solution (25.8 mL) and the mixture is stirred for 30 min at room temperature. The bromide (1.69 mL, 19.33 mmol) is added dropwise and the mixture is stirred for 30 min at room temperature and then is refluxed for 2 h. The reaction is quenched with saturated NH_4Cl and extracted with EtOAc. The combined organics are dried with MgSO_4 and concentrated in vacuo. The crude material is purified by silica gel chromatography using a gradient of 5-40% EtOAc in heptanes to yield the desired product (2.13 g) as a colorless oil.

Propargyl alcohol (2.39 mL, 41.11 mmol) is added dropwise at 0 °C to a solution of diacetylene **22-2** (2.13 g, 10.28 mmol) in anhydrous ethanol (50.0 mL). Wilkinson's catalyst (0.95 g, 1.028 mmol) is added to the mixture and it stirred overnight at room temperature. The crude reaction is concentrated in vacuo and subjected to silica gel chromatography using a gradient of 10-80%

EtOAc in heptanes. The desired fractions are collected and concentrated to afford both regioisomers **22-3** and **22-4** (1.93 g). The mixture is carried on to the next step.

To a solution of the mixture of alcohols **22-3** and **22-4** (1.93 g, 7.33 mmol) and N,N-diisopropylethylamine (1.91 mL, 10.98 mmol) in dichloromethane (50.0 mL) is added triphenylphosphine dibromide (4.73 g, 10.98 mmol) at 0 °C. The reaction is stirred for 2 h and concentrated in vacuo. The resulting residue is purified by silica gel chromatography using a gradient of 7-60% EtOAc in heptanes to yield the mixture of regioisomers **22-5** and **22-6** (2.12 g) as a white solid.

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **2-8**, bromide, **22-5**, and other appropriate starting materials and purification conditions:

Compound **256**: MS, electrospray, $m/z = 555.4$ [M+H], RT 1.13 min (Method A2);

Compound **257**: MS, electrospray, $m/z = 527.3$ [M+H], RT 1.12 min (Method A2).

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **2-8**, bromide, **22-6**, and other appropriate starting materials and purification conditions:

Compound **255**: MS, electrospray, $m/z = 555.4$ [M+H], RT 1.15 min (Method A2);

Compound **258**: MS, electrospray, $m/z = 527.3$ [M+H], RT 1.16 min (Method A2).


The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-15**, bromide, **22-5**, and other appropriate starting materials and purification conditions:

Compound **119**: MS, electrospray, $m/z = 569.3$ [M+H], RT 1.13 min (Method A2);

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, **3-15**, bromide, **22-6**, and other appropriate starting materials and purification conditions:

Compound **118**: MS, electrospray, $m/z = 569.3$ [M+H], RT 1.11 min (Method A2);

Example 23. Preparation of intermediate 5-Bromomethyl-6-methyl-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester (23-3).




The alcohol (0.968 mL, 12.94 mmol) is added dropwise at 0 °C to a solution of diacetylene **23-1** (500 mg, 2.59 mmol) in anhydrous ethanol (12.0 mL). Wilkinson's catalyst (239.4 mg, 0.259 mmol) is added to the mixture and it stirred overnight at room temperature. The crude reaction is concentrated in vacuo and subjected to silica gel chromatography using a gradient of 10-80% EtOAc in heptanes. The desired fractions are collected and concentrated yielding a solid (105 mg).

To a solution of alcohol **23-2** (105 mg, 0.399 mmol) and N,N-Diisopropylethylamine (0.104 mL, 0.598 mmol) in dichloromethane (7.0 mL) is added triphenylphosphine dibromide (263 mg, 0.598 mmol) at 0 °C. The reaction is stirred for 2 h and concentrated in vacuo. The resulting residue is purified by silica gel chromatography using a gradient of 7-60% EtOAc in heptanes to yield **23-3**.

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, **2-8**, bromide, **23-3**, and other appropriate starting materials and purification conditions:

Compound **143**: MS, electrospray, $m/z = 555.4$ $[M+H]$, RT 0.74 min.

Example 24: Preparation of 5-Ethoxy-1-(6-{3-methyl-2-[5-methyl-2-(tetrahydro-pyran-4-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-phenyl}-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (Compound 147)




Amine **12-48** (122 mg, 0.232 mmol) is combined with DMAP (2 mg, 0.02 mmol) and DIPEA (60 μ L, 0.34 mmol) in dichloromethane (5 mL) at rt. Tetrahydro-2H-pyran-4-carbonyl chloride (40 μ L, 0.23 mmol) is added, and the mixture is stirred overnight at rt. The mixture is applied directly to a samplet, and then purified by elution with 100% dichloromethane on a 50g HP-Sil SNAP cartridge (Biotage). Concentration in vacuo affords the intermediate ester (31 mg) that is used immediately in the next step.

Ester (30 mg) is dissolved in EtOH/H₂O/THF (1, 0.5, 0.5 mL) and treated with LiOH (26 mg, 1.2 mmol). The mixture is stirred at 45 °C o/n, and then concentrated under N₂. The residue is then purified by gradient elution (5-95% MeCN/water + 0.1% TFA) on a 12g KP-C18 SNAP cartridge (Biotage). The product is concentrated in vacuo, to afford **Compound 150** (26 mg).

Compound **147**: MS, electrospray, $m/z = 611.3$ $[M+H]$, RT 1.04 min (Method B1)

Example 25: Preparation of intermediate 6-Bromomethyl-8-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (25-14)



To a mixture of **25-01** (185 g; 0.940 mol), K₂CO₃ (437 g, 3.17 mol) in acetone (2 L) is added MeI (424 g, 2.99 mol). The mixture is stirred at 40 °C for 16 h. After filtration, the mixture is purified by silica gel column (PE: EtOAc = 500: 1) to give 1-Bromo-3-methoxy-5-methylbenzene, **25-02** (189 g) as a light yellow oil.

To a mixture of **25-02** (200 g, 0.995 mol) in dry THF (1.70 L) is added dropwise n-BuLi (438 ml; 1.09 mol) at -70 °C. After stirring for 1 h at -70 °C, dry DMF (76.3 g, 1.04 mol) is added dropwise at -70 °C and stirred for 1 h at -70 °C. The mixture is poured into NH₄Cl (1.00 L) and extracted with EtOAc (500 mL × 3), washed with brine (500 mL × 2), dried over Na₂SO₄ and concentrated to give 3-Methoxy-5-methyl-benzaldehyde, **25-03** (147 g) as a yellow oil.

The mixture of **25-03** (150 g, 0.999 mol) and NH₄OAc (30.8 g, 0.40 mol) in MeNO₂ (1.5 L) is refluxed for 16 h. The mixture is concentrated, then diluted with EtOAc (1000 mL), washed with water (1 L), brine (100 mL), the organic layers are dried over Na₂SO₄ and concentrated. The

mixture is triturated with PE: EtOAc = 10: 1 for 10 minutes, filtered to give 1-Methoxy-3-methyl-5-((E)-2-nitro-vinyl)-benzene, **25-04** (80 g) as yellow solid.

To a mixture of LiAlH₄ (78.6 g, 2.00 mol) in dry THF (1 L) is added **25-04** (78 g, 0.404 mol) in portions at 0 °C in THF (200 mL) and stirred for 16 h at 70 °C. The mixture is cooled to 0 °C, quenched slowly with water (78 mL), 15% NaOH (78 mL) and water (235 mL). After filtration, the mixture is concentrated to give 2-(3-Methoxy-5-methyl-phenyl)-ethylamine, **25-05** (40 g) as a light yellow oil.

The mixture of compound **25-05** (66 g, 0.40 mol) and formic acid (73.5 g, 1.60 mol) in dioxane (600 mL) is stirred for 16 h at 90 °C. The mixture was concentrated to give N-[2-(3-Methoxy-5-methyl-phenyl)-ethyl]-formamide, **25-06** (77 g) as yellow solid.

To a solution of **25-06** (76.0 g, 0.354 mol) in dichloromethane (2.5 L) is added POCl₃ (155 g, 1.01 mol) at 15 °C and refluxed for 3 h. The solution is concentrated, to the residue is added water (1.5 L), toluene (1.5 L) and 20% NaOH (500 mL), then refluxed for 1 h and cooled. The mixture is diluted with EtOAc (500 mL x 3), washed with water (1 L x 2), brine (100 mL x 2), the combined organics were dried over Na₂SO₄ and concentrated. It is purified by silica gel column (PE: EtOAc = 10: 1) to give 6-Methoxy-8-methyl-3,4-dihydro-isoquinoline, **25-07** (58.5 g) as brown oil.

To a solution of **25-07** (58.5 g, 0.334 mol) in MeOH (500 mL) is added NaBH₄ (63.3 g, 1.67 mol) at 0 °C and the mixture is maintained at 0 °C for 4 h. The solution is quenched with 1N HCl (100 mL), pH is adjusted to 8 by addition of NaHCO₃, extracted with dichloromethane (300 mL x 2), the combined organics are dried over Na₂SO₄ and concentrated to afford 6-Methoxy-8-methyl-3,4-dihydro-isoquinoline, **25-08** (83 g, crude) as brown oil.

A solution of crude **25-08** (83 g, 0.47 mol) in HBr (40% in water, 500 mL) is heated to 90 °C for 12 h. The solution is evaporated under reduced pressure to obtain 8-Methyl-1,2,3,4-tetrahydro-isoquinolin-6-ol hydrobromide, **25-09**. To this crude residue is added Boc₂O (72 g, 0.33 mol) and triethylamine (63 g, 0.62 mol) and the resulting mixture is stirred for 12 h at 15 °C, then diluted

with dichloromethane (1500 mL) and water (100 mL). The organics layer is washed with 0.5 N HCl (100 mL) and brine (100 mL), dried, concentrated, and purified by silica gel column (PE: EtOAc = 30: 1) to give 6-Hydroxy-8-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester, **25-10** (33.4 g) as a white solid.

To a solution of **25-10** (33 g; 0.113 mol) and pyridine (20.1 g, 0.254 mol) in dry dichloromethane (300 mL) is added TiF_4 (39.4 g, 0.139 mol) drop-wise at -30°C and stirred for 1 h at -30°C . Then the solution is warmed to 15°C and stirred for 8 h. The mixture is diluted with dichloromethane (500 mL) and water (100 mL), and the combined organics are concentrated and then purified by silica gel column (PE: EtOAc = 50: 1) to give 8-Methyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester, **25-11** (43 g) as a white solid.


A solution of **25-11** (43 g, 0.109 mol), Et_3N (33.0 g, 0.327 mol), DPPP (4.53 g) and $\text{Pd}(\text{OAc})_2$ (5 g) in MeOH (500 mL) is stirred under 3 MPa pressure of CO at 90°C for 2 days. After filtration and concentration the residue is purified by silica gel chromatography (PE: EtOAc = 50: 1) to afford 8-Methyl-3,4-dihydro-1H-isoquinoline-2,6-dicarboxylic acid 2-tert-butyl ester 6-methyl ester, **25-12** (21 g) as a colorless oil.

To a solution of **25-12** (21 g, 0.693 mol) in dry THF (500 mL) is added LiAlH_4 (7.4 g, 208 mmol) at -50°C . The mixture is stirred at -50°C for 1 h, and then 0°C for 30 min. The reaction is slowly quenched with H_2O (7.4 mL), 15% NaOH (7.4 mL), and H_2O (22.2 mL) and then filtered. The filtrate is concentrated and purified by prep-HPLC and concentrated. The residue is extracted with dichloromethane (1 L x 2), the combined organics were dried over Na_2SO_4 and concentrated to give 6-Hydroxymethyl-8-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester, **25-13** (14.8 g) as a colorless oil.

To a solution of **25-13** (13.4 g, 0.485 mol) and DIEA (11.8 mL, 0.679 mol) in dichloromethane (200 mL) at -30°C is added triphenylphosphine dibromide (26.6 g, 0.606 mol). The resulting mixture was stirred 1 h, over which time cold bath is allowed to warm to -10°C . Volatiles are stripped from the -10°C mixture, the residue is suspended in dichloromethane (50 mL), and the

filtrate is purified by chromatography (silica gel, 5-40% EtOAc in heptane) to provide the desired intermediate **25-14** (16.2 g) as a white solid.

Similarly, the following bromides were prepared from the appropriate starting materials as described in Example **25**:



The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **1-6**, bromide, **25-14**, and other appropriate starting materials and purification conditions:

Compound **161**: MS, electrospray, $m/z = 597.3$ [M+H], RT 0.75 min.

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **2-8**, bromide, **25-14**, and other appropriate starting materials and purification conditions:

Compound **171**: MS, electrospray, $m/z = 569.3$ [M+H], RT 0.68 min;

Compound **186**: MS, electrospray, $m/z = 541.3$ [M+H], RT 0.60 min;

Compound **237**: MS, electrospray, $m/z = 569.3$ [M+H], RT 0.60 min;

Compound **239**: MS, electrospray, $m/z = 569.3$ [M+H], RT 0.60 min;

Compound **240**: MS, electrospray, $m/z = 585.2$ [M+H], RT 0.60 min;

Compound **242**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.59 min;

Compound **244**: MS, electrospray, $m/z = 557.3$ [M+H], RT 0.62 min.

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-15**, bromide, **25-14**, and other appropriate starting materials and purification conditions:

Compound **169**: MS, electrospray, $m/z = 583.3$ [M+H], RT 0.73 min;

Compound **173**: MS, electrospray, $m/z = 583.3$ [M+H], RT 0.74 min;

Compound **174**: MS, electrospray, $m/z = 555.3$ [M+H], RT 0.72 min;

Compound **195**: MS, electrospray, $m/z = 583.4$ [M+H], RT 0.71 min;

Resolution: IC column 15% 1:1:1MeOH:EtOH:iPA + diethylamine:CO₂, 3 ml/min, 40°C, 200bar

Compound **197**: MS, electrospray, $m/z = 583.4$ [M+H], RT 0.71 min;

Resolution: IC column 15% 1:1:1MeOH:EtOH:iPA + diethylamine:CO₂, 3 ml/min, 40°C, 200bar

Compound **200**: MS, electrospray, $m/z = 583.3$ [M+H], RT 0.63 min (Method B1);

Compound **210**: MS, electrospray, $m/z = 571.1$ [M+H], RT 0.70 min (Method B1);


Compound **241**: MS, electrospray, $m/z = 569.3$ [M+H], RT 0.62 min;

Compound **243**: MS, electrospray, $m/z = 599.3$ [M+H], RT 0.63 min;

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **2-8**, bromide, **25-15**, and other appropriate starting materials and purification conditions:

Compound **121**: MS, electrospray, $m/z = 569.4$ [M+H], RT 0.72 min.

Example 26: Preparation of intermediate 6-Bromomethyl-8-methyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (26-12).



A round-bottom flask is charged with 2-Hydroxy-4-iodo-benzoic acid methyl ester, **26-01** (12.0 g, 43.2 mmol), 2,4,6-Trivinyl-cyclotriphosphoroxane-pyridine complex (11.4 g, 47.5 mmol), tetrakis(triphenylphosphine) palladium (2.49 g, 2.16 mmol), 2.0 M aqueous solution of sodium carbonate (25.9 mL, 51.7 mmol), and 1,2-dimethoxyethane (50 mL), deoxygenated by alternating between vacuum and argon (3x), and refluxed under argon pressure for 3 h, and then stirred 18 h at ambient temperature. Volatiles are stripped in vacuo, the residue is suspended in 1N HCl (800 mL) and extracted with EtOAc (600 mL, 300 mL, and then 300 mL). The combined organic extracts are washed brine, dried over NaSO_4 , and purified by chromatography (silica gel, 5-30% EtOAc in heptane) to afford 2-Hydroxy-4-vinyl-benzoic acid, **26-02** (3.70 g) and 2-Hydroxy-4-vinyl-benzoic acid methyl ester (0.300 g).

To a solution of **26-02** (3.70 g, 22.0 mmol) and 2-Hydroxy-4-vinyl-benzoic acid methyl ester (0.300 g, 1.69 mmol) in MeOH (50 mL) is added H₂SO₄ (4.0 mL, 75 mmol). The resulting mixture is refluxed for 16 h and then allowed to cool to room temperature. Ice (100 g) is added and the mixture is stirred. When the ice completely melts, the MeOH is removed under reduced pressure and the aqueous residue is extracted with DCM (2x 100 mL). The combined organic extracts are combined, concentrated *in vacuo* and purified by chromatography (silica gel, 0-5% EtOAc in heptane) to give 2-Hydroxy-4-vinyl-benzoic acid methyl ester, **26-03** (3.75 g) as a clear oil.

To a stirring mixture of **26-03** (3.75 g, 21 mmol) and Sodium metaperiodate (13.8 g, 64.3 mmol) in THF (80 mL) and water (20 mL) is added a 4 wt% solution of osmium tetroxide in water (3.69 mL, 0.47 mmol). The reaction flask (which warms upon addition of the osmium reagent) is wrapped in aluminum foil to shield contents from light, and the slurry is stirred 16 h. Volatiles are removed under reduced pressure, the residue is diluted with saturated aqueous NaHCO₃ (700 mL) and extracted with EtOAc (700 mL, 200 mL, and then 200 mL). Combined organic extracts are concentrated *in vacuo* and then purified by chromatography (silica gel, 0-50% EtOAc in heptane) to afford 4-Formyl-2-hydroxy-benzoic acid methyl ester, **26-04** (2.25 g) as a yellow solid.

In a round-bottom flask with Dean Stark trap attached, **26-04** (2.25g, 12 mmol) and aminoacetaldehyde dimethyl acetal (1.31 g, 12 mmol) are refluxed in toluene 3 h. Reaction mixture is concentrated *in vacuo* to afford crude 4-{{2,2-Dimethoxy-ethylimino}-methyl}-2-hydroxy-benzoic acid methyl ester, **26-05** (3.33 g, 12.4 mmol) as a brown oil. To this crude oil is added a large stir bar, polyphosphoric acid (25.0 g), and phosphorous pentoxide (33.0 g, 232 mmol). The resulting, viscous tar is stirred at 80 °C for 5 h. The reaction mixture is diluted with H₂O (600 mL), transferred to a 5 L Erlenmyer flask, and the vigorously stirred mixture is carefully treated with small portions of solid NaHCO₃ until said addition no longer cause receiving mixture to foam. Basic aqueous mixture is then extracted with DCM (5 x 200 mL). The combined organic extracts are washed with H₂O (2 x 50 mL), dried with Na₂SO₄, concentrated under *vacuo* and then purified by chromatography (silica gel, 0-100% EtOAc in heptane) to yield 5-Hydroxy-isoquinoline-6-carboxylic acid methyl ester, **26-06** (0.520 g).

26-06 (0.520 g, 2.46 mmol) is dissolved in MeOH (15 mL) and then 4N HCl in dioxane (6.15 mL, 24 mmol) is added. Hydrogenated on an H-Cube apparatus by continuously cycling solution through a PtO₂ cartridge at a rate of 1mL / minute under 10 mbar of H₂-pressure for 5 h, then under 50 mbar H₂-pressure for 15 h. Reaction mixture is concentrated under reduced pressure to get crude 5-Hydroxy-1,2,3,4-tetrahydro-isoquinoline-6-carboxylic acid methyl ester; hydrochloride, **26-07** (0.90 g) as a red solid. This crude solid is dissolved in DCM (30 mL) and cooled to 0 °C before adding triethylamine (1.65 mL, 11 mmol) and then di-tert-butyl dicarbonate (1.70 mL, 7.39 mmol). Reaction mixture is removed from cold bath, stirred 16 h, concentrated under reduced pressure and purified by chromatography (silica gel, 0-50% EtOAc in heptane). Desired intermediate 5-Hydroxy-3,4-dihydro-1H-isoquinoline-2,6-dicarboxylic acid 2-tert-butyl ester 6-methyl ester **26-08** (0.492 g) co-elutes with di-tert-butyl dicarbonate (1.61g). The mixture (2.1 g) is dissolved in MeOH (50 mL), K₂CO₃ (2.21 g, 16 mmol) is added and the resulting mixture is stirred 16 h. Supernatant is removed from reaction flask and sediment is triturated with MeOH (2 x 10 mL). The combined methanolic supernatants are concentrated under reduced pressure, dissolved in EtOAc (50 mL), washed with 1N HCl (3 x 30 mL), brine (10 mL), dried with Na₂SO₄, and concentrated in vacuo to get **26-08** (0.422g). This residue is combined with iodomethane (1.0 mL, 16 mmol), K₂CO₃ (0.20 g, 1.5 mmol), Cs₂CO₃ (0.40 g, 1.5 mmol), and acetone (4.0 mL) and irradiated in microwave at 70 °C for 7 h. Mixture is concentrated under reduced pressure and purified by chromatography (silica gel, 0-100% EtOAc) to afford impure 5-Methoxy-3,4-dihydro-1H-isoquinoline-2,6-dicarboxylic acid 2-tert-butyl ester 6-methyl ester, **26-09** (0.245 g) which was carried forward *as is*.

Impure **26-09** (0.240 g, 0.51 mmol) is combined with lithium hydroxide (1.22 g, 5.1 mmol) in THF (4.0 mL), MeOH (4.0 mL) and water (2.0 mL). The mixture is heated 45 minutes at 55 °C and then concentrated under reduced pressure. The residue is dissolved in EtOAc (20 mL), washed with 1N HCl (3 x 50mL), brine (10 mL), dried with Na₂SO₄, and concentrated in vacuo to give crude 5-Methoxy-3,4-dihydro-1H-isoquinoline-2,6-dicarboxylic acid 2-tert-butyl ester, **26-10** (0.177 g) as a white solid.

To a solution of crude **26-10** (0.177 g, 0.58 mmol) in THF (3 mL) is added a 1M borane in THF solution (1.27 mL, 1.27 mmol) and the resulting mixture is stirred for 18 h. Reaction mixture is concentrated in vacuo and purified by reverse-phase chromatography (C18 silica gel, 5-95 % MeCN, in H₂O with 0.1 % TFA) to get 6-Hydroxymethyl-5-methoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester, **26-11** (0.125 g) as a clear, colorless residue.


26-11 (0.125 g, 0.43 mmol) and N,N-diisopropylethylamine (0.111 mL, 0.64 mmol) are dissolved in DCM (4.0 mL), the resulting mixture is deoxygenated by alternating between argon and vacuum (3x), and then cooled to -30 °C. Triphenylphosphine dibromide (0.262 g, 0.60 mmol) is added and the resulting mixture stirs for 3 h as cold bath warms to -15 °C. Reaction mixture is concentrated under reduced pressure and the residue is purified by chromatography (silica gel, 5-50% EtOAc in heptane) to afford desired intermediate 6-Bromomethyl-5-methoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester, **26-12** (0.103 g).

The following compound from Table 1 is prepared according to the procedure described in Example **7a**, using phenol, **3-15**, bromide, **26-12**, and other appropriate starting materials and purification conditions:

Compound **220**: MS, electrospray, m/z = 599.3 [M+H], RT 0.71 min;

Compound **221**: MS, electrospray, m/z = 571.3 [M+H], RT 0.71 min;

Example 27: 5-Methoxy-1-(6-{3-methyl-2-[5-methyl-1-oxo-2-(tetrahydro-pyran-4-yl)-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy]-phenyl}-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid




To a suspension of compound **27** (0.065 g, 0.11 mmol) in a 4:1 mixture of 1,1,2,2-tetrachloroethane:water (1.2 mL) is added sodium chlorite (0.035 g, 0.39 mmol). The mixture was heated at 55°C for 2 hours then cooled to room temperature and the mixture purified by C18 flash reverse phase chromatography to afford the title compound (0.009 g).

Compound **167**: MS, electrospray, m/z = 584.8 [M+H], RT 1.01 min.

The following compound is prepared according to the above procedure using Compound **114** as the appropriate starting materials and purification conditions:

Compound **194**: MS, electrospray, m/z = 597.22 [M+H], RT 1.02 min.

Example 28: Preparation of 1-{6-[2-(2-(S)-1-[1,4]Dioxan-2-ylmethyl-5-methyl-1,2,3,4-tetrahydro-isoquinolin-6-ylmethoxy)-3-methyl-phenyl]-pyridin-2-yl}-5-ethoxy-1H-pyrazole-4-carboxylic acid



Amine **8-42** (80.0 mg, 0.152 mmol) is dissolved in acetonitrile (3.0 mL) and chloride (16.87 mg, 0.182 mmol) and Cs₂CO₃ (51.5 mg, 0.243 mmol) are added. The reaction is heated to 60 °C and stirred overnight. LC-MS indicated the desired mass. The reaction is extracted with EtOAc, washed with brine, dried over MgSO₄, and concentrated. The resulting residue is subjected to silica gel chromatography using a gradient of 12-100% EtOAc in heptanes. The desired fractions are collected and concentrated to yield the product (43.0 mg).

To a solution of epoxide **28-1** (43.0 mg, 0.074 mmol) and DCE (2.0 mL) is added 2-chloroethanol (0.005 mL, 0.081 mmol) followed by a solution of BF₃Et₂O (0.01 mL) in DCE. The reaction is stirred at 45 °C overnight. The reaction mixture is cooled to room temperature and is concentrated. The resulting material is carried on crude to the next step.


To starting material **28-2** (40.0 mg) is added a solution of 2.0 M NaOH (2.0 mL). This solution is heated to 90 °C and becomes homogeneous. It is stirred for 3 h and the reaction is cooled to room temperature. It is subjected to a C18 column (20-80% ACN in Water with 0.1% TFA). The desired fractions were collected and concentrated to yield the desired compound **18** (19.1 mg).

Compound **185**: MS, electrospray, *m/z* = 599.3 [M+H], RT 0.75 min, Method B1.

The following compound is prepared according to the procedure described in Example **28**, using the appropriate starting materials and purification conditions:

Compound **170**: MS, electrospray, *m/z* = 599.3 [M+H], RT 0.63 min, Method B1.

Example 29: tert-Butyl 8-ethyl-6(hydroxymethyl)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate (29-13)



To the mixture of compound **29-1** (300 g, 1.6 mol) and K_2CO_3 (665 g, 4.8 mol) in DMF (2000 mL) was added MeI (250 g, 1.8 mol) dropwisely at room temperature. The mixture was stirred overnight. TLC showed the reaction is completed. The reaction was quenched by H_2O and extracted with EtOAc. The organic layer was dried, filtered, evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **29-2** (165 g, 52% yield).

The solution of compound **29-2** (100 g, 497.4 mmol), NBS (88.5 g, 497.4 mmol) and AIBN (10 g, 10%) in CCl_4 (700 mL) was heated to reflux for 12 h. TLC showed the reaction is completed.

After cooling down to room temperature, the reaction was quenched by H₂O and extracted with EtOAc. The organic layer was dried, filtered and evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **29-3** (48 g, 42% yield).

The solution of compound **29-3** (80 g, 285.7 mmol) and TMSCN (28.2 g, 285.7 mmol) in ACN (600 ml) was stirred at room temperature for 0.5 h. TBAF (74.6 g, 285.7 mmol) was added into the reaction mixture at ice based and the mixture was stirred for 12 h. TLC showed the reaction was completed. The reaction was quenched by H₂O and extracted with EtOAc. The organic layer was dried, filtered and evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **29-4** (39 g, 60% yield).

The solution of compound **29-4** (12 g, 53.1 mmol) and Ni (10 g) in MeOH (80 ml) and NH₃.H₂O (80 ml) was stirred under H₂ with a pressure of 50 psi at room temperature for 5 h. TLC showed the reaction was completed. The mixture was filtered and the filtrate was concentrate on vacuum pump to give the crude product (8 g) which was used directly in the next step.

The solution of compound **29-5** (75 g, 326.08 mmol) and HCHO (8.8 g, 293.47 mmol) in HCO₂H (500 ml) was stirred at 50 °C under N₂ overnight. LCMS showed the reaction was completed. The solvent was removed under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **29-6** (54 g, 64% yield for 2 steps).

The solution of compound **29-6** (45 g, 186 mmol) in aqueous HBr solution (400 ml) was stirred at 90 °C for 12 h. LCMS showed the reaction was completed. The solvent was removed under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **29-7** (20.75 g, 53% yield).

The solution of compound **29-7** (20 g, 87.7 mmol), Boc₂O (19.1 g, 87.7 mmol) and TEA (17.7 g, 175.4 mmol) in THF/H₂O (1:1) (200 ml) was stirred at room temperature for 3 h. TLC showed the reaction is completed. The reaction was quenched by H₂O and extracted with EtOAc. The organic layer was dried, filtered and evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **29-8** (20 g, 70% yield).

The solution of compound **29-8** (14 g, 42.7 mmol), K_2CO_3 (17.66 g, 128 mmol), $Pd(dppf)Cl_2$ (2.5 g), $Pd(PPh_3)_4$ (2.5 g), and compound **29-8B** (7.22 g, 46.9 mmol) in DMF (150 ml) was stirred at reflux overnight. TLC showed the reaction is completed. After filtration, the filtrate was concentrate under reduced pressure and the residue was purified by chromatography on silica gel to give compound **29-9** (7.2 g, 61% yield).

The solution of compound **29-9** (7.2 g, 26.2 mmol) and Pd-C (2 g) in MeOH (100 ml) was stirred under H_2 with a pressure of 50 psi at room temperature for 12 h. TLC showed the reaction was completed. The mixture was filtered and the filtrate was concentrated to give crude product which was purified by chromatography on silica gel to give compound **29-10** (5.8g, 80% yield).

The solution of compound **29-10** (5.8 g, 20.9 mmol), Tf_2O (5.9 g, 20.9 mmol) and TEA (6.3 g, 62.7 mmol) in DCM (70 ml) was stirred at room temperature for 3 h. TLC showed the reaction was completed. The reaction was quenched by H_2O and extracted with EtOAc. The organic layer was dried, filtered and evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **29-11** (7 g, 82% yield).

A mixture of compound **29-11** (7 g, 17.1 mmol), $Pd(OAc)_2$ (1.4 g), dppp (1.4 g) and Et_3N (5.2 g, 51.3 mmol) in MeOH (80 mL) was stirred at 80 °C under CO with a pressure of 3 MPa for 2 d. The solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel to give compound **29-12** (4.8 g, 88% yield).

To a solution of $LiAlH_4$ (1.1 g, 30.1 mmol) in THF (10 mL) was added dropwise the solution of compound **29-12** (4.8 g, 15.0 mmol) in THF (50 mL) at -50 °C over 30 min. After addition, the reaction mixture was stirred at 0 °C for 2.5 h. Then the reaction mixture was treated with H_2O and DCM. The organic layer was separated, washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel to give **29-13** (4.1 g, 92% yield).


Similarly, the bromide was prepared from **29-13** as described in Example 25 producing compound **29-14**.

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, 2-8, bromide, 29-14, and other appropriate starting materials and purification conditions:

Compound **248**: MS, electrospray, $m/z = 583.3$ [M+H], RT 1.29 min (Method A2);

Compound **249**: MS, electrospray, $m/z = 555.3$ [M+H], RT 1.37 min (Method A2).

Example 30: tert-Butyl 8-cyano-6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (30-12)



To the mixture of compound **30-1** (300 g, 1.6 mol) and K_2CO_3 (665 g, 4.8 mol) in DMF (2000 mL) was added MeI (250 g, 1.8 mol) dropwisely at room temperature. The mixture was stirred overnight. TLC showed the reaction is completed. The reaction was quenched by H_2O and extracted with EtOAc. The organic layer was dried, filtered, evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **30-2** (165 g, 52% yield).

The solution of compound **30-2** (100 g, 497.4 mmol), NBS (88.5 g, 497.4 mmol) and AIBN (10 g, 10%) in CCl_4 (700 mL) was heated to reflux for 12 h. TLC showed the reaction is completed. After cooling down to room temperature, the reaction was quenched by H_2O and extracted with EtOAc. The organic layer was dried, filtered and evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **30-3** (48 g, 42% yield).

The solution of compound **30-3** (80 g, 285.7 mmol) and TMSCN (28.2 g, 285.7 mmol) in ACN (600 ml) was stirred at room temperature for 0.5 h. TBAF (74.6 g, 285.7 mmol) was added into the reaction mixture at ice based and the mixture was stirred for 12 h. TLC showed the reaction was completed. The reaction was quenched by H_2O and extracted with EtOAc. The organic layer was dried, filtered and evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **30-4** (39 g, 60% yield).

The solution of compound **30-4** (12 g, 53.1 mmol) and Ni (10 g) in MeOH (80 ml) and $\text{NH}_3 \cdot \text{H}_2\text{O}$ (80 ml) was stirred under H_2 with a pressure of 50 psi at room temperature for 5 h. TLC showed the reaction was completed. The mixture was filtered and the filtrate was concentrate on vacuum pump to give the crude product (8 g) which was used directly in the next step.

The solution of compound **30-5** (75 g, 326.08 mmol) and HCHO (8.8 g, 293.47 mmol) in HCO_2H (500 ml) was stirred at 50 °C under N_2 overnight. LCMS showed the reaction was completed. The solvent was removed under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **30-6** (54 g, 64% yield for 2 steps).

The solution of compound **30-6** (45 g, 186 mmol) in aqueous HBr solution (400 ml) was stirred at 90 °C for 12 h. LCMS showed the reaction was completed. The solvent was removed under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **30-7** (20.75 g, 53% yield).

The solution of compound **30-7** (20 g, 87.7 mmol), Boc_2O (19.1 g, 87.7 mmol) and TEA (17.7 g, 175.4 mmol) in THF/ H_2O (1:1) (200 ml) was stirred at room temperature for 3 h. TLC showed

the reaction is completed. The reaction was quenched by H₂O and extracted with EtOAc. The organic layer was dried, filtered and evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **30-8** (20 g, 70% yield).

A solution of compound **30-8** (11 g, 34.8 mmol), Pd(dppf)Cl₂ (2.5 g), Pd (PPh₃)₄ (2.5 g), ZnCN (2.8 g, 31.3 mmol), Zn (1.1 g, 17.4 mmol) in DMF (110 ml) was stirred at reflux overnight. TLC showed the reaction was completed. After filtration, the filtrate was concentrate under reduced pressure and the residue was purified by chromatography on silica gel to give compound **30-9** (6.5 g, 71% yield).

The solution of compound **30-9** (12 g, 43.7 mmol), Tf₂O (12.3 g, 43.7 mmol) and TEA (13.3 g, 131.23mmol) in DCM (120 ml) was stirred at room temperature for 3 h. TLC showed the reaction was completed. The reaction was quenched by H₂O and extracted with EtOAc. The organic layer was dried, filtered and evaporated under reduced pressure to give the crude product which was purified by chromatography on silica gel to give compound **30-10** (9 g, 51% yield).

A mixture of compound **30-10** (9.5 g, 23.4 mmol), Pd(OAc)₂ (1.9 g), dppp (1.9 g) and Et₃N (7.1 g, 70.1 mmol) in MeOH (90 mL) was stirred at 80 °C under CO with a pressure of 3 MPa for 2 d. The solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel to give compound **30-11** (6 g, 80% yield).

To a solution of LiAlH₄ (1.4 g, 37.9 mmol) in THF (10 mL) was added dropwise the solution of compound **30-11** (6 g, 19.0 mmol) in THF (50 mL) at -50 °C over 30 min. After addition, the reaction mixture was stirred at -20 °C for 4.5 h. Then the reaction mixture was treated with H₂O and DCM. The organic layer was separated, washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel to give **30-12** (4.1 g, 74% yield).

Similarly, the bromide was prepared from **30-12** as described in Example 25 producing compound **30-13**.

The following compound from Table 1 is prepared according to the procedure described in Example 7a, using phenol, 2-8, bromide, 30-13, and other appropriate starting materials and purification conditions:

Compound 250: MS, electrospray, m/z = 580.2 [M+H], RT 0.61 min.

ASSESSMENT OF BIOLOGICAL ACTIVITY

Cellular Assay

The sGC cellular activator assay is performed in the presence and absence of 50% human serum (HS) using Chinese hamster ovary cells that have been stably transfected to express the human soluble guanylate cyclase alpha 1 and beta 1 subunits (sGC). Cells are preincubated with 40 microM 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), an sGC inhibitor, for one h in buffer containing 0.1% bovine serum albumin and 3-isobutyl-1-methylxanthine (IBMX). Concentration response curves are prepared for test compounds in DMSO. An intermediate dilution of the compounds is performed in either buffer containing IBMX or type AB HS containing IBMX. Diluted compounds are added to cells and they are incubated at room temperature for thirty min. cGMP is measured using a CisBio homogeneous time resolved fluorescence kit and the EC₅₀ is calculated for each compound.

Representative compounds of the present invention were tested for activity the above assay. Preferred compounds have an EC₅₀ of <1,000 nM in the above assay and more preferred compounds have an EC₅₀ < 200 nM. As examples, data for representative compounds from Table 1 are shown in Table 2.

Table 2

Compound Number	EC ₅₀ (nM)	Compound Number	EC ₅₀ (nM)
-----------------	-----------------------	-----------------	-----------------------

1	39	130	21
2	11	131	410
3	29	132	11
4	11	133	27
5	9.	134	46
6	87	135	54
7	32	136	81
8	42	137	89
9	59	138	54
10	16	139	8.4
11	17	140	15
12	26	141	17
13	180	142	62
14	18	143	160
15	28	144	460
16	23	145	13
17	18	146	23
18	8	147	450
19	17	148	43
20	24	149	44
21	17	150	91
22	14	151	130
23	52	152	14
24	54	153	26
25	16	154	28
26	5	155	86
27	14	156	720
28	13	157	25
29	3.5	158	30
30	10	159	53
31	19	160	110
32	170	161	14
33	97	162	23
34	65	163	55
35	29	164	32
36	27	165	11
37	120	166	6.6
38	66	167	30
39	17	168	580
40	62	169	13
41	27	170	28

42	24	171	16
43	130	172	50
44	44	173	13
45	26	174	14
46	38	175	40
47	22	176	9.7
48	10	177	35
49	54	178	14
50	990	179	59
51	72	180	28
52	170	181	62
53	110	182	370
54	110	183	980
55	110	184	12
56	820	185	30
57	24	186	16
58	82	187	14
59	31	188	8.6
60	--	189	12
61	59	190	23
62	24	191	3.3
63	82	192	10
64	71	193	12
65	56	194	87
66	110	195	4.7
67	320	196	13
68	38	197	19
69	61	198	5.3
70	180	199	9
71	67	200	20
72	17	201	12
73	250	202	12
74	73	203	4.4
75	23	204	4.5
76	160	205	13
77	31	206	7.4
78	48	207	9.2
79	33	208	20
80	45	209	200
81	410	210	19
82	8	211	30

83	29	212	36
84	9	213	39
85	22	214	30
86	41	215	37
87	55	216	110
88	28	217	35
89	150	218	62
90	69	219	140
91	75	220	150
92	20	221	210
93	37	222	5.4
94	45	223	8.5
95	54	224	79
96	24	225	10
97	67	226	12
98	270	227	13
99	160	228	14
100	170	229	3.9
101	110	230	13
102	110	231	4.6
103	110	232	9.5
104	31	233	11
105	17	234	13
106	27	235	20
107	23	236	28
108	24	237	4.9
109	34	238	5.1
110	45	239	6.5
111	99	240	7.9
112	110	241	8
113	24	242	11
114	40	243	16
115	68	244	23
116	28	245	280
117	29	246	6.5
118	39	247	8.6
119	57	248	4.2
120	12	249	4.6
121	40	250	44
122	23	251	7
123	55	252	10

124	47	253	13
125	27	254	25
126	58	255	9.5
127	7.5	256	14
128	15	257	14
129	17	258	15

ASSESSMENT OF SOLUBILITY

Solubility is measured by the following method.

1. Sample preparation:

100 uL, 10 mM DMSO stock solution of each compound is prepared in a 96 well plate format. The experiment is done in single determination at 3 pH values (2.2, 4.5 and 6.8). For each pH and one reference, 40 uL of each compound is needed.

Buffer preparation:

McIlvaine pH 2.2: To 2.076 g citric acid monohydrate and 0.043 g $\text{Na}_2\text{HPO}_4 \times 2\text{H}_2\text{O}$ add 100 ml deionized water

McIlvaine pH 4.5: To 1.166 g citric acid monohydrate and 1.585 g $\text{Na}_2\text{HPO}_4 \times 2\text{H}_2\text{O}$ add 100 ml deionized water

McIlvaine pH 6.8: To 0.476 g citric acid monohydrate and 2.753 g $\text{Na}_2\text{HPO}_4 \times 2\text{H}_2\text{O}$ add 100 ml deionized water

With a suitable liquid handling device (Multipette® or a liquid handler) 390 uL of each buffer solution and 10 uL of compound is added to each well of a 96 deep well plate. The plates are covered firmly and shaken for 24 h on an over head shaker (at 54 RPM) at room temperature. The DMSO content in the final buffer is 2.5% v/v.

After 24 h the plates are centrifuged to remove droplets on the lid before opening (for ~5 min at 2500 RPM).

The filtration is done under vacuum with Millipore 96 well filter plate. Filtrate is collected in a deep well plate and transferred to a suitable plate for UPLC analysis.

The reference plate is prepared by adding 10 μ L of compound to 390 μ L of 50:50 acetonitrile/water in a 96 deep well plate and transferred to a suitable plate for UPLC analysis. Wells are checked visually for precipitation, any presence noted under comments in reported results.

2. Sample measurement

The samples are measured with UPLC-UV using the chromatographic method described below.

stationary phase	Waters ACQUITY UPLC® BEH C18 1.7 μ m 2.5x50 mm
mobile phase	
solvent A	0.1 % formic acid (pH 3)
solvent B	acetonitrile with 0.1 % formic acid
Gradient	
0 min	5 % B
1.0 min	95 % B
1.3 min	95 % B
1.4 min	5 % B
1.7 min	5 % B
column temperature	40°C
Flow	0.8 mL/min
duration/cycle time	1.7 min/2.7 min
injection volume	2 μ L
sample temperature	20 °C
PDA detection	Enable 3D data
wavelength	254 nm

sampling rate	40 points/sec
resolution	4.8 nm

Waters Empower®2 software is used for generating Sample Sets (according to the plate layout), Sample Set Methods and Instrument Methods.

One Sample Set comprises the methods for three 96 well plates (one reference plate and two sample plates, and includes one Sample Set Method and one Instrument Method).

3. Data Processing and Analysis

The UV chromatograms collected at 254 nm are integrated and processed.

It is assumed that the compound is completely dissolved in the reference solution (50:50 acetonitrile/water)

Solubility data ($\mu\text{g/mL}$) for compounds from Table 1 is shown in Table 3 below.

Table 3

Compound Number	(pH 2.2)	(pH 4.5)	(pH 6.8)
1	95	80	87
2	110	83	88
3	96	79	81
4	100	81	83
5	98	76	72
6	90	64	81
7	110	77	91
8	110	82	98
9	94	70	82
10	94	50	73
11	23	<0.1	80
12	110	90	92
13	100	84	87
14	110	82	76
15	110	88	90
16	95	71	81

17	97	62	85
18	110	86	90
19	96	70	75
20	95	72	68
21	96	62	60
22	97	68	73
23	99	79	82
24	95	76	76
25	91	38	39
26	100	80	80
27	110	88	90
28	110	83	90
29	110	79	78
30	100	81	75
31	110	89	94
32	91	73	78
33	93	73	75
34	82	65	68
35	93	73	78
36	91	72	74
37	92	74	78
38	110	94	88
39	93	44	81
40	99	81	85
41	96	75	80
42	93	75	78
43	95	79	82
44	100	85	88
45	82	61	73
46	100	82	86
47	87	69	79
48	100	82	86
49	92	69	58
50	120	79	75
51	110	83	93
52	83	58	73
53	84	65	70
54	100	78	75
55	98	48	49
56	87	66	77
57	95	47	51

58	111	85	89
59	--	--	--
60	117	96	100
61	130	110	99
62	110	88	91
63	110	90	92
64	100	66	66
65	110	84	74
66	63	54	55
67	90	76	78
68	85	71	74
69	91	77	80
70	86	57	64
71	94	75	78
72	44	46	67
73	86	67	71
74	110	83	95
75	120	93	90
76	100	86	89
77	96	83	87
78	100	86	89
79	100	87	89
80	110	94	95
81	100	84	79
82	120	100	97
83	110	88	95
84	110	86	89
85	120	96	110
86	110	90	91
87	110	87	90
88	90	63	75
89	130	92	81
90	100	81	81
91	100	81	81
92	110	93	96
93	98	77	81
94	91	68	73
95	100	80	84
96	93	67	75
97	91	72	77
98	150	110	99

99	150	120	110
100	110	88	97
101	90	73	74
102	99	81	82
103	96	78	81
104	110	93	97
105	93	72	75
106	88	69	73
107	73	54	58
108	81	61	65
109	88	33	36
110	130	96	120
111	87	69	75
112	110	78	94
113	94	80	84
114	120	99	100
115	89	71	43
116	--	--	--
117	102	82	85
118	110	84	92
119	110	89	97
120	110	94	97
121	110	90	93
122	100	86	82
123	100	76	73
124	100	8.6	44
125	110	76	78
126	96	74	78
127	130	100	110
128	93	77	78
129	95	79	79
130	130	100	110
131	130	97	110
132	130	110	110
133	120	99	100
134	110	94	100
135	110	97	100
136	120	100	110
137	110	98	110
138	--	--	--
139	130	110	120

140	140	120	120
141	130	110	110
142	120	87	93
143	160	150	160
144	110	89	93
145	110	92	94
146	100	88	79
147	1.2	3.1	75
148	110	100	94
149	110	78	81
150	100	67	78
151	110	98	85
152	97	74	74
153	87	67	65
154	85	36	57
155	60	66	73
156	--	--	--
157	94	70	62
158	64	43	41
159	86	55	51
160	<0.1	0.93	73
161	110	91	97
162	100	83	82
163	110	75	73
164	100	72	93
165	120	58	39
166	110	51	64
167	2.1	5.9	83
168	110	90	88
169	120	100	97
170	120	96	95
171	120	99	98
172	110	87	85
173	130	98	97
174	99	71	91
175	110	80	85
176	100	77	43
177	110	58	86
178	100	72	86
179	43	92	93
180	100	79	76

181	110	87	88
182	110	81	81
183	110	82	87
184	89	76	76
185	100	83	82
186	110	83	99
187	100	82	83
188	89	77	73
189	89	73	75
190	100	83	87
191	100	85	80
192	--	--	--
193	100	80	73
194	0.68	2.5	78
195	110	83	80
196	89	77	85
197	110	83	79
198	120	100	93
199	120	96	92
200	100	73	73
201	87	68	66
202	92	73	70
203	81	70	72
204	82	72	73
205	99	73	81
206	90	71	76
207	82	68	73
208	82	47	57
209	110	81	84
210	110	87	87
211	95	82	78
212	92	79	75
213	85	66	72
214	81	64	69
215	86	70	76
216	--	--	--
217	97	73	69
218	120	85	75
219	110	76	74
220	100	77	86
221	100	72	94

222	85	71	73
223	81	68	69
224	110	78	13
225	95	78	81
226	98	83	86
227	90	73	77
228	96	78	81
229	100	81	73
230	100	84	72
231	120	92	87
232	93	74	63
233	98	73	86
234	120	97	91
235	100	83	88
236	110	96	83
237	94	55	52
238	77	55	52
239	91	71	72
240	92	69	67
241	100	81	84
242	110	79	78
243	100	82	81
244	120	99	98
245	100	79	92
246	--	--	--
247	90	75	71
248	94	75	74
249	94	67	93
250	110	81	86
251	100	72	77
252	94	73	62
253	100	75	81
254	100	64	80
255	--	--	--
256	--	--	--
257	--	--	--
258	--	--	--

ASSESSMENT OF METABOLIC STABILITY

Objective

The 5 time point, high-throughput human liver microsome (HLM) metabolic stability assay is designed to determine *in vitro* compound metabolism. Compounds are incubated with HLMs at a concentration of 1 μ M, at 37°C, for a total of 60 min. The percent of compound remaining at 5, 15, 30, and 60 min is used to calculate the $t_{1/2}$ (min), CL_{int} (mL/min/kg), CL_h (mL/min/kg), and % Q_h . The assay is based on a 96-well format and can accommodate up to 92 compounds per plate (n=1).

Incubation

Using the 96-well multi-channel head, the Biomek FX, equipped with a Peltier heating block/shaker, is programmed to accomplish the following steps:

1. Pipette 175 μ L of 1.15 mg/mL microsomes into each of the 96 conical inserts (Analytical Sales and Products, catalog number 96PL05) that fit into the plate of the Peltier heating block/shaker (the incubation plate)
2. Add 5 μ L of compounds from the assay plate to the microsomes and shake the mixture at 600 rpm at 42.1°C for 10 min (a setting of 42.1°C on the Peltier is required for the samples to incubate at 37°C)
3. After 10 min, prompt the user to add the NADPH plate to the deck and add 20 μ L from the NADPH plate to the incubation plate to start the reaction
4. Add 215 μ L of 100%, cold acetonitrile containing an internal standard(s) to a 0 minute, 5 minute, 15 minute, 30 minute, and 60 minute “quench” plate
5. At 0 min, 5 min, 15 min, 30 min, and 60 min into the incubation, aspirate 12 μ L from the incubation mixture and add it to the quench solution to stop the reaction
6. Add 185 μ L HPLC grade water to each well of the 0, 5, 15, 30 and 60 minute quench plates to dilute compounds to the appropriate concentration for the mass spectrometer

After all time points are collected, the quench plates are sealed with 96-well pierceable plate mats or heat sealing foil and centrifuged at 3000 rpm for 15 min to pellet the microsomes.

Analysis

The plates are analyzed using LC/MS/MS with electron spray ionization (ESI) and the previously determined MRM transitions. The LC method includes the following parameters:

Injection volume: 5 uL

Mobile Phases: 0.1% Formic Acid in Water (A) and 0.1% Formic Acid in Acetonitrile (B) (HPLC grade)

Left and Right Temperature: 35 °C

Run Time: 4.0 min

Column: Thermo Scientific, Aquasil C18, 50 x 2.1 mm, 5 µ, part number 77505-052130, or equivalent

LC Pump Gradient:

Total Time (min)	Flow Rate (uL/min)	%A	%B
0	500	90.0	10.0
0.5	500	90.0	10.0
1.5	500	1.0	99.0
2.5	500	1.0	99.0
3.3	500	90.0	10.0
4.0	500	90.0	10.0

If peak shape is poor and cannot be integrated properly, the following LC method can be used:

Injection volume: 5 uL

Mobile Phases: 2.5 mM Ammonium Bicarbonate (A) and 100% Acetonitrile (B) (HPLC grade)

Aqueous Wash: 90% Water, 10% Acetonitrile (HPLC grade)

Organic Wash: 90% Acetonitrile, 10% Water (HPLC grade)

Left and Right Temperature: 35°C

Run Time: 4.5 min

Column: Phenomex Luna 3u C18(2) 100A, 50 x 2.00 mm

LC Pump Gradient:

Total Time	Flow Rate (uL/min)	%A	%B
------------	--------------------	----	----

(min)			
0	500	90.0	10.0
0.5	500	90.0	10.0
1.5	500	1.0	99.0
2.5	500	1.0	99.0
3.30	500	90.0	10.0
4.50	500	90.0	10.0

Using an Excel template in Activitybase, the peak areas corresponding to 5, 15, 30 and 60 min are compared to the peak area at 0 min to calculate the percent of remaining compound using the following equation:

Percent compound remaining = (AUC at Time t min/AUC at Time 0 min) x 100 where t = 0, 5, 15, 30 or 60 min.

Time (min) is plotted against the natural logarithm (Ln) of the percent compound remaining to determine the slope. The slope is used to calculate $t_{1/2}$ (min) using the equation, $t_{1/2} = 0.693/\text{slope}$.

Cl_{int}, Intrinsic clearance

- $0.693/t_{1/2} \times \text{Avg liver wt in g/avg body wt in kg} \times f(u)/\text{protein concentration in incubation in mg/mL} \times \text{mg microsomal protein/g liver}$
- $0.693/t_{1/2} \times 26 \text{ g/kg} \times 1/1.0 \text{ mg/mL} \times 45 \text{ mg/g}$

Cl_h, Hepatic clearance

- $\text{Hepatic flow} \times f(u) \times \text{Cl}_{int}/(\text{hepatic flow} + f(u) \times \text{Cl}_{int})$

Q_h, % Hepatic blood flow

- $(\text{Cl}_h/\text{Hepatic flow}) \times 100$

Metabolic stability data (%Qh) for compounds from Table 1 is shown in Table 4 below.
Preferred compounds have %Qh values of less than 24.

Table 4

Compound Number.	HLM (%Qh)	Compound Number.	HLM (%Qh)
1	<24	130	25
2	<24	131	28
3	<24	132	<24
4	<24	133	<24
5	<24	134	32
6	<24	135	29
7	<24	136	<24
8	<24	137	<24
9	<24	138	68
10	30	139	<24
11	47	140	<24
12	<24	141	<24
13	<24	142	<24
14	31	143	<24
15	<24	144	<24
16	<24	145	<24
17	31	146	<24
18	<24	147	<24
19	29	148	<24
20	38	149	<24
21	<24	150	<24
22	33	151	<24
23	<24	152	<24
24	<24	153	<24
25	29	154	<24
26	29	155	<24
27	<24	156	<24
28	<24	157	31
29	28	158	<24
30	<24	159	<24
31	<24	160	44
32	<24	161	<24
33	<24	162	26

34	<24	163	<24
35	<24	164	<24
36	<24	165	<24
37	<24	166	27
38	<24	167	<24
39	<24	168	<24
40	<24	169	<24
41	<24	170	<24
42	<24	171	<24
43	26	172	<24
44	<24	173	<24
45	<24	174	<24
46	<24	175	31
47	<24	176	28
48	<24	177	<24
49	48	178	<24
50	40	179	<24
51	<24	180	<24
52	<24	181	<24
53	<24	182	<24
54	<24	183	<24
55	<24	184	<24
56	<24	185	<24
57	<24	186	<24
58	<24	187	<24
59	<24	188	<24
60	<24	189	26
61	<24	190	43
62	<24	191	<24
63	<24	192	<24
64	<24	193	<24
65	<24	194	<24
66	<24	195	<24
67	<24	196	<24
68	<24	197	<24
69	<24	198	<24
70	<24	199	<24
71	<24	200	40
72	47	201	<24
73	36	202	<24
74	<24	203	<24

75	31	204	<24
76	<24	205	<24
77	<24	206	<24
78	<24	207	<24
79	<24	208	<24
80	<24	209	<24
81	<24	210	<24
82	<24	211	<24
83	<24	212	<24
84	<24	213	<24
85	<24	214	<24
86	<24	215	<24
87	<24	216	<24
88	<24	217	89
89	76	218	89
90	<24	219	89
91	<24	220	<24
92	<24	221	<24
93	<24	222	<24
94	<24	223	<24
95	<24	224	<24
96	30	225	<24
97	<24	226	52
98	31	227	25
99	<24	228	44
100	31	229	34
101	<24	230	<24
102	<24	231	<24
103	25	232	<24
104	26	233	26
105	<24	234	<24
106	<24	235	29
107	<24	236	<24
108	<24	237	<24
109	<24	238	<24
110	<24	239	25
111	<24	240	<24
112	<24	241	<24
113	<24	242	<24
114	<24	243	<24
115	25	244	<24

116	<24	245	<24
117	25	246	<24
118	<24	247	<24
119	<24	248	<24
120	<24	249	<24
121	<24	250	<24
122	<24	251	<24
123	<24	252	<24
124	<24	253	<24
125	<24	254	<24
126	<24	255	<24
127	<24	256	<24
128	<24	257	<24
129	<24	258	<24

METHODS OF THERAPEUTIC USE

The compounds disclosed herein effectively activate soluble guanylate cyclase. The activation or potentiation of soluble guanylate cyclase is an attractive means for preventing and treating a variety of diseases or conditions associated with deficient sGC activation. Thus, in one embodiment of the invention, there are provided methods of treating diseases that can be alleviated by sGC activation or potentiation. These include:

Cardiovascular and related diseases including hypertension, atherosclerosis, peripheral artery disease, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, thromboembolic pulmonary hypertension, pulmonary arterial hypertension, stable and unstable angina and thromboembolic disorders;

Inflammatory diseases including psoriasis, multiple sclerosis, arthritis, asthma, and chronic obstructive pulmonary disease;

Hepatic fibrotic disorders including but not limited to cirrhosis of any etiology or fibrosis of specific areas of the liver such as periportal fibrosis which may be caused by immunologic injury, hemodynamic effects and/or other causes;

Renal fibrotic disorders including but not limited to glomerulosclerosis, focal glomerulosclerosis, mesangial fibrosis, interstitial fibrosis due to immunologic injury, hemodynamic effects, diabetes (types I and 2), , diabetic nephropathy, IgA nephropathy, lupus nephropathy, membranous nephropathy, hypertension, hemolytic uremic syndrome, multiple glomerulonephritides, interstitial nephritis, tubulointerstitial nephritis again of immunologic and non-immunologic causes;

Pulmonary fibrotic disorders, both diffuse and localized, due to immunologic and non-immunologic causes, including but not limited to idiopathic pulmonary fibrosis, pulmonary fibrosis due to exposure to toxins, chemicals, drugs, and cystic fibrosis;

Cardiac fibrotic disorders due to immunologic and non-immunologic causes including ischemic heart disease (coronary artery disease) and transient and/or sustained decreased blood flow in one or more coronary vessels including possibly related to interventions on coronary arteries or veins, associated with cardiac surgery and/or the use of cardiopulmonary bypass procedures and myocarditis due to viral and non-viral causes, as well as immunologically related myocardial injury potentially due to cross-reactivity to other antigens to which the human body is exposed;

Other diseases mediated at least partially by diminished or decreased soluble guanylate cyclase activity, such as renal disease, diabetes, urologic disorders including overactive bladder, benign prostatic hyperplasia, and erectile dysfunction, and neurological disorders including Alzheimer's disease, Parkinson's disease and neuropathic pain.

These disorders have been well characterized in man, but also exist with a similar etiology in other mammals, and can be treated by pharmaceutical compositions of the present invention.

For therapeutic use, the compounds of the invention may be administered via a pharmaceutical composition in any conventional pharmaceutical dosage form in any conventional manner.

Conventional dosage forms typically include a pharmaceutically acceptable carrier suitable to the particular dosage form selected. Routes of administration include, but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by infusion, sublingually, transdermally, orally, topically or by inhalation. The preferred modes of administration are oral and intravenous.


The compounds of this invention may be administered alone or in combination with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including other active ingredients. In one embodiment, for example, multiple compounds of the present invention can be administered. Advantageously, such combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies. Compounds of the invention may be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition. Advantageously, the compounds may then be administered together in a single dosage form. In some embodiments, the pharmaceutical compositions comprising such combinations of compounds contain at least about 5%, but more preferably at least about 20%, of a compound of formula (I) (w/w) or a combination thereof. The optimum percentage (w/w) of a compound of the invention may vary and is within the purview of those skilled in the art. Alternatively, the compounds of the present invention and the conventional therapeutics or other adjuvants may be administered separately (either serially or in parallel). Separate dosing allows for greater flexibility in the dosing regimen.

As mentioned above, dosage forms of the compounds of this invention may include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art and suitable to the dosage form. These carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances. Preferred dosage forms include tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule, suppository and transdermal patch. Methods for preparing such dosage forms are known (see, for example, H.C. Ansel and N.G. Popovich, *Pharmaceutical Dosage Forms and Drug Delivery*

Systems, 5th ed., Lea and Febiger (1990)). Dosage levels and requirements for the compounds of the present invention may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. In some embodiments, dosage levels range from about 1-1000 mg/dose for a 70 kg patient. Although one dose per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. As the skilled artisan will appreciate, lower or higher doses may be required depending on particular factors. For instance, specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician.

What is claimed is:

1. A compound of the formula I



I

wherein:

A is a 5-7 membered saturated heterocyclyl group containing one nitrogen and optionally one oxygen, wherein one carbon of said heterocyclyl group is optionally substituted with one or two groups selected from C₁₋₃alkyl and oxo ;

R¹ is C₁₋₄ alkyl optionally substituted with a methoxy group;

R² is selected from H, F, Cl, C₁₋₃alkyl, -CN, -OMe and -CF₃;

R³ is selected from H and -CH₃;

R⁴ is selected from H, F, -CH₃ and -OMe;

R⁵ is selected from H, Cl, -CH₃, -CH₂CH₃, -CF₃, F, and -OMe;

R^6 is bonded to the nitrogen on A and is selected from H, C_{1-6} alkyl, $-(CH_2)_n C_{3-6}$ cycloalkyl, $-C(O)C_{1-6}$ alkyl, $-(CH_2)_n$ heterocyclyl, $-(CH_2)_n$ aryl $-(CH_2)_n$ heteroaryl, $-SO_2$ aryl, SO_2C_{1-6} alkyl wherein said C_{1-6} alkyl, $-(CH_2)_n$ heterocyclyl, $-(CH_2)_n$ cycloalkyl, $-(CH_2)_n$ aryl and $-(CH_2)_n$ heteroaryl are optionally substituted with one to four groups independently selected from C_{1-3} alkyl, halogen, C_{1-3} alkoxy, $-CF_3$, $-OH$, oxo, $-(CH_2)_{1-3}O(CH_2)_{2-3}OH$, and $-SO_2CH_3$;

R^7 is selected from H, $-CH_3$, $-CH_2CH_3$, $-CF_3$, F, and $-CN$;

n is 0, 1 or 2

or a salt thereof.

2. The compound according to claim 1, wherein:

A is a 5-7 membered saturated heterocyclyl group containing one nitrogen, wherein one carbon of said heterocyclyl group is optionally substituted with one or two C_{1-3} alkyl groups;

R^1 is C_{1-3} alkyl;

R^2 is selected from H, F, Cl, C_{1-3} alkyl, $-CN$, $-OMe$ and $-CF_3$;

R^3 is selected from H and $-CH_3$;

R^4 is selected from H and F;

R^5 is selected from H, Cl and $-CH_3$;

R^6 is bonded to the nitrogen on A and is selected from H, C_{1-6} alkyl, $-(CH_2)_n C_{3-6}$ cycloalkyl, $-C(O)C_{1-6}$ alkyl, $-(CH_2)_n$ heterocyclyl, $-(CH_2)_n$ aryl and $-(CH_2)_n$ heteroaryl, wherein said C_{1-6}

alkyl, $-(CH_2)_n$ heterocyclyl, $-(CH_2)_n$ cycloalkyl, $-(CH_2)_n$ aryl and $-(CH_2)_n$ heteroaryl are optionally substituted with one to four groups independently selected from C_{1-3} alkyl, halogen, C_{1-3} alkoxy, $-CF_3$, $-OH$ and $-SO_2CH_3$;

R^7 is H;

and


n is 0, 1 or 2;

or a salt thereof.





3. The compound according to claim 1 or 2, wherein:

R^1 is methyl, ethyl or isopropyl; and

the group



is selected from:



and

;

or a salt thereof.

4. The compound according to any of claims 1 to 3, wherein:

R^2 is selected from $-CH_3$, F, Cl, and $-CF_3$; and

R^6 is selected from H, C_{1-6} alkyl, $-(CH_2)_n C_{3-6}$ cycloalkyl, $-C(O)C_{1-6}$ alkyl and $-(CH_2)_n$ heterocyclyl, wherein said C_{1-6} alkyl, $-(CH_2)_n$ cycloalkyl and $-(CH_2)_n$ heterocyclyl are optionally substituted with one to four groups independently selected from C_{1-3} alkyl, halogen, C_{1-3} alkoxy, $-CF_3$, $-OH$ and $-SO_2CH_3$;

or a salt thereof.

5. The compound according to any of claims 1 to 4, wherein each heterocyclyl referred to in R^6 is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 2-oxabicyclo[3.2.0]heptanyl, [1,4]dioxanyl, 8-oxabicyclo[3.2.1]octanyl, 1-oxaspiro[4.5]decanyl and pyrrolidin-2-one;

each heteroaryl referred to in R^6 is selected from imidazolyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl and 4,5,6,7-tetrahydrobenzothiazolyl;

and each aryl referred to in R^6 is phenyl;

or a salt thereof.

6. The compound according to any of claims 1 to 5, wherein:

R^6 is $-(CH_2)_n$ heterocyclyl, wherein said heterocyclyl is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 2-oxabicyclo[3.2.0]heptanyl, [1,4]dioxanyl, 8-oxabicyclo[3.2.1]octanyl and 1-oxaspiro[4.5]decanyl;

or a salt thereof.

7. The compound according to any of claims 1 to 6, wherein:

R^2 is $-\text{CH}_3$;

R^3 is H;

R^4 is H or $-\text{CH}_3$;


R^5 is H, or $-\text{CH}_3$;

R^7 is in the position para to R^5 and is H, $-\text{CH}_3$ or $-\text{CH}_2\text{CH}_3$;


or a salt thereof.

8. The compound according to any of claims 1 to 7, wherein:

the group



is



or a salt thereof.





9. The compound according to any of claims 1 to 8, wherein:









R^3 is H; and









R^4 is H;









or a salt thereof.









10. The compound according to claim 1 selected from the group consisting of









Cpd No.	Structure	Cpd No.	Structure
1		2	
3		4	









5		6	
7		8	
9		10	
11		12	









13		14	
15		16	
17		18	
19		20	









21		22	
23		24	
25		26	
27		28	









29		30	
31		32	
33		34	
35		36	









37		38	
39		40	
41		42	
43		44	









45		46	
47		48	
49		50	
51		52	









53		54	
55		56	
57		58	
59		60	









61		62	
63		64	
65		66	
67		68	









69		70	
71		72	
73		74	
75		76	









77		78	
79		80	
81		82	
83		84	









85		86	
87		88	
89		90	
91		92	









93		94	
95		96	
97		98	
99		100	









101		102	
103		104	
105		106	
107		108	

109		110	
111		112	
113		114	
115		116	









117		118	
119		120	
121		122	
123		124	

125		126	
127		128	
129		130	
131		132	









133		134	
135		136	
137		138	
139		140	









141		142	
143		144	
145		146	
147		148	

149		150	
151		152	
153		154	
155		156	









165		166	
167		168	
169		170	
171		172	









173		174	
175		176	
177		178	
179		180	









181		182	
183		184	
185		186	
187		188	









189		190	
191		192	
193		194	
195		196	

197		198	
199		200	
201		202	
203		204	







205		206	
207		208	
209		210	
211		212	

213		214	
215		216	
217		218	
219		220	

221		222	
223		224	
225		226	
227		228	

237		238	
239		240	
241		242	
243		244	

245		246	
247		248	
249		250	
251		252	

253		254	
255		256	
257		258	


and the pharmaceutically acceptable salts thereof.

11. The compound according to claim 10 selected from the group consisting of compound numbers 1, 2, 3, 4, 5, 7, 8, 9, 12, 15, 16, 18, 21, 27, 28, 30, 31, 35, 36, 39, 41, 42, 44, 45, 46, 47, 48, 57, 59, 62, 68, 77, 78, 79, 80, 82, 83, 84, 85, 86, 88, 92, 93, and 94 and the pharmaceutically acceptable salts thereof.

12. The compound according to claim 10 selected from the group consisting of compound numbers 95, 97, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,


116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 136, 137,
139, 140, 141, 142, 145, 146, 152, 153, 154, 155, 157, 158, 159, 161, 162, 163, 164, 165, 166,
167, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 184, 185, 186, 187, 188,
189, 191, 193, 194, 195, 196, 197, 198, 199, 201, 202, 203, 204, 205, 206, 207, 208, 210, 211,
5 212, 213, 214, 215, 216, 220, 222, 223, 224, 225, 227, 229, 230, 231, 232, 233, 234, 235, 236,
237, 238, 239, 240, 241, 242, 243, 244, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,
257 and the pharmaceutically acceptable salts thereof.

13. The compound according to claim 1 wherein the compound is




or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 wherein the compound is




or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 1 wherein the compound is



or a pharmaceutically acceptable salt thereof.


16. The compound according to claim 1 wherein the compound is



or a pharmaceutically acceptable salt thereof.


5

17. The compound according to claim 1 wherein the compound is




or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 1 wherein the compound is




or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 1 wherein the compound is




or a pharmaceutically acceptable salt thereof.

- 5 20. The compound according to claim 1 wherein the compound is




or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 1 wherein the compound is



or a pharmaceutically acceptable salt thereof.

22. The compound according to claim 1 wherein the compound is



or a pharmaceutically acceptable salt thereof.

23. A pharmaceutical composition comprising a compound according to any of claims 1 to 22 and a pharmaceutically acceptable excipient or carrier.

24. A compound according to any of claims 1 to 22 for use in treating a disease or disorder that can be alleviated by sGC activation or potentiation.

25. The compound according to claim 24 wherein the disease or disorder is selected from a cardiovascular disease, inflammatory disease, hepatic fibrotic disorder, renal fibrotic disorder, pulmonary fibrotic disorder and cardiac fibrotic disorder.

26. The compound according to claim 24 wherein the disease is selected from renal disease, overactive bladder, benign prostatic hyperplasia, erectile dysfunction, Alzheimer's disease, Parkinson's disease and neuropathic pain.

27. The compound according to claim 24 wherein the disease is diabetic nephropathy.

28. Use of a compound according to any of claims 1 to 22 in the manufacture of a medicament for the treatment of a disease or disorder selected from the group consisting of a cardiovascular disease, inflammatory disease, hepatic fibrotic disorder, renal fibrotic disorder, pulmonary fibrotic disorder and cardiac fibrotic disorder.

29. Use of a compound according to any of claims 1 to 22 in the manufacture of a medicament for the treatment of a disease selected from the group consisting of a renal disease, overactive bladder, benign prostatic hyperplasia, erectile dysfunction, Alzheimer's disease, Parkinson's disease and neuropathic pain.

5

30. Use of a compound according to any of claims 1 to 22 in the manufacture of a medicament for the treatment of diabetic nephropathy.

10